

2016

THE MASTER OF PHARMACY (M. PHARM.) COURSE REGULATION 2014

(BASED ON NOTIFICATION IN THE GAZETTE OF INDIA No. 362, DATED DECEMBER 11, 2014)

SCHEME AND SYLLABUS



PHARMACY COUNCIL OF INDIA
Combined Council's Building, Kotta Road,
Aiwan-E-Ghalb Marg, New Delhi-110 002.
Website : www.pci.nic.

Table of Contents

S.No.	Content	Page.No.
	Regulations	01
1.	Short Title and Commencement	01
2.	Minimum qualification for admission	01
3.	Duration of the program	01
4.	Medium of instruction and examinations	01
5.	Working days in each semester	01
6.	Attendance and progress	02
7.	Program/Course credit structure	02
8.	Academic work	03
9.	Course of study	03
10.	Program Committee	15
11.	Examinations/Assessments	16
12.	Promotion and award of grades	32
13.	Carry forward of marks	32
14.	Improvement of internal assessment	33
15.	Reexamination of end semester examinations	33
16.	Allowed to keep terms (ATKIP)	33
17.	Grading of performances	33
18.	The Semester grade point average (SGPA)	34
19.	Cumulative Grade Point Average (CGPA)	34
20.	Declaration of class	35
21.	Project work	35
22.	Award of Ranks	36
23.	Award of degree	36
24.	Duration for completion of the program of study	36
25.	Revaluation / Retotaling of answer papers	36
26.	Re-admission after break of study	36
27.	Pharmaceutics (MPH)	37
28.	Industrial Pharmacy (MIP)	55
29.	Pharmaceutical Chemistry (MPC)	73
30.	Pharmaceutical Analysis (MPA)	98
31.	Pharmaceutical Quality Assurance (MQA)	119
32.	Pharmaceutical Regulatory Affairs (MRA)	149
33.	Pharmaceutical Biotechnology (MPB)	165
34.	Pharmacy Practice (MPP)	188
35.	Pharmacology (MPL)	209
36.	Pharmacognosy (MPG)	232
37.	Research Methodology & Biostatistics (MRM)	252

भारतीय शासकीय पत्रिका-33004/09

REGD. NO. D. 3. 14003/09


भारत का राजपत्र
The Gazette of India

अधिसूचना
EXTRAORDINARY
PART III—SUB 4
PART III—Section 4
विभाग 4 अ. 4
PUBLISHED BY AUTHORITY

र. 3621
No. 3621

नई दिल्ली, मंगलवार, दिनांक 11, 2014/अग्रहायण 20, 1936
NEW DELHI, THURSDAY, DECEMBER 11, 2014/AGRAHAYANA, 20, 1936

PHARMACY COUNCIL OF INDIA
NOTIFICATION

New Delhi, the 10th December, 2014

The Master of Pharmacy (M.Pharm) Course Regulations, 2014

No. 14-1366-2014-PCB.—In exercise of the powers conferred by Sections 10 and 18 of the Pharmacy Act, 1948, the Pharmacy Council of India, with the approval of the Central Government hereby makes the following regulations, namely—

CHAPTER -I:REGULATIONS

1. Short Title and Commencement

These regulations shall be called as "The Revised Regulations for the Master of Pharmacy (M. Pharm.) Degree Program - Credit Based Semester System (CBSS) of the Pharmacy Council of India, New Delhi". They shall come into effect from the Academic Year 2016-17. The regulations framed are subject to modifications from time to time by the authorities of the university.

2. Minimum qualification for admission

A Pass in the following examinations

a) B. Pharm Degree examination of an Indian university established by law in India from an institution approved by Pharmacy Council of India and has scored not less than 55 % of the maximum marks (aggregate of 4 years of B.Pharm.)

b) Every student, selected for admission to post graduate pharmacy program in any PCI approved institution should have obtained registration with the State Pharmacy Council or should obtain the same within one month from the date of his/her admission, failing which the admission of the candidate shall be cancelled.

Note: It is mandatory to submit a migration certificate obtained from the respective university where the candidate had passed his/her qualifying degree (B.Pharm.)

3. Duration of the program

The program of study for M.Pharm. shall extend over a period of four semesters (two academic years). The curricula and syllabi for the program shall be prescribed from time to time by Pharmacy Council of India, New Delhi.

4. Medium of instruction and examinations

Medium of instruction and examination shall be in English.

5. Working days in each semester

Each semester shall consist of not less than 100 working days. The odd semesters shall be conducted from the month of June/July to November/December and the even semesters shall be conducted from the month of December/January to May/June in every calendar year.

6. Attendance and progress

A candidate is required to put in at least 80% attendance in individual courses considering theory and practical separately. The candidate shall complete the prescribed course satisfactorily to be eligible to appear for the respective examinations.

7. Program/Course credit structure

As per the philosophy of Credit Based Semester System, certain quantum of academic work viz. theory classes, practical classes, seminars, assignments, etc. are measured in terms of credits. On satisfactory completion of the courses, a candidate earns credits. The amount of credit associated with a course is dependent upon the number of hours of instruction per week in that course. Similarly the credit associated with any of the other academic, co/extra-curricular activities is dependent upon the quantum of work expected to be put in for each of these activities per week/per activity.

7.1. Credit assignment

7.1.1. Theory and Laboratory courses

Courses are broadly classified as Theory and Practical. Theory courses consist of lecture (L) and Practical (P) courses consist of hours spent in the laboratory. Credits (C) for a course is dependent on the number of hours of instruction per week in that course, and is obtained by using a multiplier of one (1) for lecture and a multiplier of half (1/2) for practical (laboratory) hours. Thus, for example, a theory course having four lectures per week throughout the semester carries a credit of 4. Similarly, a practical having four laboratory hours per week throughout semester carries a credit of 2.

The contact hours of seminars, assignments and research work shall be treated as that of practical courses for the purpose of calculating credits. i.e., the contact hours shall be multiplied by 1/2. Similarly, the contact hours of journal club, research work presentations and discussions with the supervisor shall be considered as theory course and multiplied by 1.

7.2. Minimum credit requirements

The minimum credit points required for the award of M. Pharm. degree is 95. However based on the credit points earned by the students under the head of co-curricular activities, a student shall earn a maximum of 100 credit points. These credits are divided into Theory courses, Practical, Seminars, Assignments, Research work, Discussions with the supervisor, Journal club and Co-Curricular activities over the duration of four semesters. The credits

are distributed semester-wise as shown in Table 14. Courses generally progress in sequence, building competencies and their positioning indicates certain academic maturity on the part of the learners. Learners are expected to follow the semester-wise schedule of courses given in the syllabus.

8. Academic work

A regular record of attendance both in Theory, Practical, Seminar, Assignment, Journal club, Discussion with the supervisor, Research work presentation and Dissertation shall be maintained by the department / teaching staff of respective courses.

9. Course of study

The specializations in M.Pharm program is given in Table 1.

Table – 1: List of M.Pharm. Specializations and their Code

S. No.	Specialization	Code
1.	Pharmaceutics	MPH
2.	Industrial Pharmacy	MIP
3.	Pharmaceutical Chemistry	MPC
4.	Pharmaceutical Analysis	MPA
5.	Pharmaceutical Quality Assurance	MQA
6.	Pharmaceutical Regulatory Affairs	MRA
7.	Pharmaceutical Biotechnology	MPB
8.	Pharmacy Practice	MPP
9.	Pharmacology	MPL
10.	Pharmacognosy	MPG

The course of study for M.Pharm specializations shall include Semester wise Theory & Practical as given in Table - 2 to 11. The number of hours to be devoted to each theory and practical course in any semester shall not be less than that shown in Table - 2 to 11.

Table - 3: Course of study for M. Pharm. (Industrial Pharmacy)

Course Code	Course	Credit Hours	Credit Points	Hrs./week	Marks
Semester I					
MIP101T	Modern Pharmaceutical Analytical Techniques	4	4	4	100
MIP102T	Pharmaceutical Formulation Development	4	4	4	100
MIP103T	Novel drug delivery systems	4	4	4	100
MIP104T	Intellectual Property Rights	4	4	4	100
MIP105P	Industrial Pharmacy Practical I	12	6	12	150
	Seminar Assignment	7	4	7	100
Total		35	26	35	650
Semester II					
MIP201T	Advanced Biopharmaceutics and Pharmacokinetics	4	4	4	100
MIP202T	Scale up and Technology Transfer	4	4	4	100
MIP203T	Pharmaceutical Production Technology	4	4	4	100
MIP204T	Entrepreneurship Management	4	4	4	100
MIP205P	Industrial Pharmacy Practical II	12	6	12	150
	Seminar Assignment	7	4	7	100
Total		35	26	35	650

Table - 7: Course of study for M. Pharm. (Regulatory Affairs)

Course Code	Course	Credit Hours	Credit Points	Hrs./wk	Marks
Semester I					
MRA 101T	Good Regulatory Practices	4	4	4	100
MRA 102T	Documentation and Regulatory Writing	4	4	4	100
MRA 103T	Clinical Research Regulations	4	4	4	100
MRA 104T	Regulations and Legislation for Drugs & Cosmetics, Medical Devices, Biologicals & Herbs, and Food & Nutraceuticals in India and Intellectual Property Rights	4	4	4	100
MRA 105P	Regulatory Affairs Practical I	12	6	12	150
	Seminar Assignment	7	4	7	100
	Total	35	26	35	650
Semester II					
MRA 201T	Regulatory Aspects of Drugs & Cosmetics	4	4	4	100
MRA 202T	Regulatory Aspects of Herbal & Biologicals	4	4	4	100
MRA 203T	Regulatory Aspects of Medical Devices	4	4	4	100
MRA 204T	Regulatory Aspects of Food & Nutraceuticals	4	4	4	100
MRA 205P	Regulatory Affairs Practical II	12	6	12	150
	Seminar Assignment	7	4	7	100
	Total	35	26	35	650

Table - 10: Course of study for (Pharmacology)

Course Code	Course	Credit Hours	Credit Points	Hrs./wk	Marks
Semester I					
MPL 101T	Modern Pharmaceutical Analytical Techniques	4	4	4	100
MPL 102T	Advanced Pharmacology I	4	4	4	100
MPL 103T	Pharmacological and Toxicological Screening Methods-I	4	4	4	100
MPL 104T	Cellular and Molecular Pharmacology	4	4	4	100
MPL 105P	Pharmacology Practical I	12	6	12	150
	Seminar Assignment	7	4	7	100
	Total	35	26	35	650
Semester II					
MPL 201T	Advanced Pharmacology II	4	4	4	100
MPL 202T	Pharmacological and Toxicological Screening Methods-II	4	4	4	100
MPL 203T	Principles of Drug Discovery	4	4	4	100
MPL 204T	Experimental Pharmacology Practical-II	4	4	4	100
MPL 205P	Pharmacology Practical II	12	6	12	150
	Seminar Assignment	7	4	7	100
	Total	35	26	35	650

Table - 12: Course of study for M. Pharm. III Semester
(Common for All Specializations)

Course Code	Course	Credit Hours	Credit Points
MRM301T	Research Methodology and Biostatistics	4	4
-	Journal club	1	1
-	Discussion /Presentation (Proposal Presentation)	2	2
-	Research Work	28	14
	Total	35	21

* Non University Exam

Table - 13: Course of study for M. Pharm. IV Semester
(Common for All Specializations)

Course Code	Course	Credit Hours	Credit Points
	Journal Club		
-	Research Work	31	16
	Discussion Final Presentation	3	3
	Total	35	20

Table - 14: Semester wise credits distribution

Semester	Credit Points
I	26
II	26
III	21
IV	20
Co-curricular Activities (Attending Conference, Scientific Presentations and Other Scholarly Activities)	Minimum-02 Maximum-07*
Total Credit Points	Minimum=95 Maximum=100*

*Credit Points for Co-curricular Activities

Table - 15: Guidelines for Awarding Credit Points for Co-curricular Activities

Name of the Activity	Maximum Credit Points Eligible / Activity
Participation in National Level Seminar/Conference/Workshop/Symposium/ Training Programs (related to the specialization of the student)	01
Participation in international Level Seminar/Conference/Workshop/Symposium/ Training Programs (related to the specialization of the student)	02
Academic Award/Research Award from State Level/National Agencies	01
Academic Award/Research Award from International Agencies	02
Research / Review Publication in National Journals (Indexed in Scopus / Web of Science)	01
Research / Review Publication in International Journals (Indexed in Scopus / Web of Science)	02

Note: International Conference: Held Outside India

International Journal: The Editorial Board Outside India

*The credit points assigned for extracurricular and or co-curricular activities shall be given by the Principals of the colleges and the same shall be submitted to the University. The criteria to acquire this credit point shall be defined by the colleges from time to time.

10. Program Committee

1. The M. Pharm. programme shall have a Programme Committee constituted by the Head of the institution in consultation with all the Heads of the departments.
2. The composition of the Programme Committee shall be as follows:
A teacher at the cadre of Professor shall be the Chairperson; One Teacher from each M.Pharm specialization and four student representatives (two from each academic year), nominated by the Head of the institution.
3. Duties of the Programme Committee:
 - i. Periodically reviewing the progress of the classes.
 - ii. Discussing the problems concerning curriculum, syllabus and the conduct of classes.
 - iii. Discussing with the course teachers on the nature and scope of assessment for the course and the same shall be announced to the students at the beginning of respective semesters.

iv. Communicating its recommendation to the Head of the institution on academic matters.

v. The Programme Committee shall meet at least twice in a semester preferably at the end of each sessional exam and before the end semester exam.

11. Examinations/Assessments

The schemes for internal assessment and end semester examinations are given in Table - 16.

11.1. End semester examinations

The End Semester Examinations for each theory and practical course through semesters I to IV shall be conducted by the respective university except for the subject with asterix symbol (*) in table I and II for which examinations shall be conducted by the subject experts at college level and the marks/grades shall be submitted to the university.

Tables - 1717 : Schemes for internal assessments and end semester
(Industrial Pharmacy- MIP)

Course Code	Course	Internal Assessment				End Semester Exams		Total Marks
		Continuous Mode	Sessional Exams		Total	Marks	Duration	
			Marks	Duration				
SEMESTER I								
MIP101T	Modern Pharmaceutical Analytical Techniques	10	15	1 Hr	25	75	3 Hrs	100
MIP102T	Pharmaceutical Formulation Development	10	15	1 Hr	25	75	3 Hrs	100
MIP103T	Novel drug delivery systems	10	15	1 Hr	25	75	3 Hrs	100
MIP104T	Intellectual Property Rights	10	15	1 Hr	25	75	3 Hrs	100
MIP105P	Industrial Pharmacy Practical I	20	30	6 Hrs	50	100	6 Hrs	150
	Seminar Assignment							100
Total								650
SEMESTER II								
MIP201T	Advanced Biopharmaceutics and Pharmacokinetics	10	15	1 Hr	25	75	3 Hrs	100
MIP202T	Scale up and Technology Transfer	10	15	1 Hr	25	75	3 Hrs	100
MIP203T	Pharmaceutical Production Technology	10	15	1 Hr	25	75	3 Hrs	100
MIP204T	Entrepreneurs Hip Management	10	15	1 Hr	25	75	3 Hrs	100

MIP205P	Industrial Pharmacy Practical II	20	30	6 Hrs	50	100	6 Hrs	150
	Seminar Assignment							100
Total								650

Tables - 21: Schemes for internal assessments and end semester examinations
(Pharmaceutical Regulatory Affairs-MRA)

Course Code	Course	Internal Assessment				End Semester Exams		Total Marks
		Cont into us Mod e	Sessional Exams		Tot al	Mar ks	Dura tion	
			Mar ks	Durati on				
SEMESTER I								
MRA10 1T	Good Pharmaceutical Practices	10	15	1 Hr	25	75	3 Hrs	100
MRA10 2T	Documentation and Regulatory Writing	10	15	1 Hr	25	75	3 Hrs	100
MRA10 3T	Clinical Research Regulations	10	15	1 Hr	25	75	3 Hrs	100
MRA10 4T	Regulations and Legislation for Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals In India and Intellectual Property Rights	10	15	1 Hr	25	75	3 Hrs	100
MRA10 5T	Pharmaceutical Regulatory Affairs Practical I	20	30	6 Hrs	50	100	6 Hrs	150
	Seminar Assignment							100
Total								650
SEMESTER II								
MRA20 1T	Regulatory Aspects of Drugs & Cosmetics	10	15	1 Hr	25	75	3 Hrs	100

MRA20 2T	Regulatory Aspects of Herbal & Biologicals	10	15	1 Hr	25	75	3 Hrs	100
MRA20 3T	Regulatory Aspects of Medical Devices	10	15	1 Hr	25	75	3 Hrs	100
MRA20 4T	Regulatory Aspects of Food & Nutraceuticals	10	15	1 Hr	25	75	3 Hrs	100
MRA20 5P	Pharmaceutical Regulatory Affairs Practical II	20	30	6 Hrs	50	100	6 Hrs	150
	Seminar Assignment							100
Total								650

Tables - 24: Schemes for internal assessments and end semester examinations
(Pharmacology-MPL)

Course Code	Course	Internal Assessment				End Semester Exams		Total Marks
		Continuous Mode	Sessional Exams		Total	Marks	Duration	
			Marks	Duration				
SEMESTER I								
MPL10 1T	Modern Pharmaceutical Analytical Techniques	10	15	1 Hr	25	75	3 Hrs	100
MPL10 2T	Advanced Pharmacology-I	10	15	1 Hr	25	75	3 Hrs	100
MPL10 3T	Pharmacological and Toxicological Screening Methods-I	10	15	1 Hr	25	75	3 Hrs	100
MPL10 4T	Cellular and Molecular Pharmacology	10	15	1 Hr	25	75	3 Hrs	100
MPL10 5P	Experimental Pharmacology - I	20	30	6 Hrs	50	100	6 Hrs	150
	Seminar Assignment							100
Total								650
SEMESTER II								
MPL20 1T	Advanced Pharmacology II	10	15	1 Hr	25	75	3 Hrs	100
MPL20 2T	Pharmacological and Toxicological Screening Methods-II	10	15	1 Hr	25	75	3 Hrs	100
MPL20 3T	Principles of Drug Discovery	10	15	1 Hr	25	75	3 Hrs	100
MPL20 4T	Clinical research and pharmacovigilance	10	15	1 Hr	25	75	3 Hrs	100
MPL20 5P	Experimental Pharmacology - II	20	30	6 Hrs	50	100	6 Hrs	150
	Seminar Assignment							100
Total								650

Tables – 26: Schemes for internal assessments and end semester examinations
(Semester III& IV)

Course Code	Course	Internal Assessment				End Semester Exams		Total Marks
		Continuous Mode	Sessional Exams		Total	Marks	Duration	
			Marks	Duration				
SEMESTER III								
MRM301T	Research Methodology and Biostatistics*	10	15	1 Hr	25	75	3 Hrs	100
-	Journal club	-	-	-	25	-	-	25
-	Discussion / Presentation (Proposal Presentation)	-	-	-	50	-	-	50
-	Research work	-	-	-	-	350	1 Hr	350
Total								525
SEMESTER IV								
-	Journal club	-	-	-	25	-	-	25
-	Discussion / Presentation (Proposal Presentation)	-	-	-	75	-	-	75
-	Research work and Colloquium	-	-	-	-	400	1 Hr	400
Total								500

*Non University Examination

11.2. Internal assessment: Continuous mode

The marks allocated for Continuous mode of Internal Assessment shall be awarded as per the scheme given below.

Table - 27: Scheme for awarding internal assessment: Continuous mode

Theory	
Criteria	Maximum Marks
Attendance (Refer Table - 28)	8
Student - Teacher interaction	2
Total	10
Practical	
Attendance (Refer Table - 28)	10
Based on Practical Records, Regular viva voce, etc	10
Total	20

Table - 28: Guidelines for the allotment of marks for attendance

Percentage of Attendance	Theory	Practical
95 - 100	8	10
90 - 94	6	7.5
85 - 89	4	5
80 - 84	2	2.5
Less than 80	0	0

11.2.1. Sessional Exams

Two sessional exams shall be conducted for each theory / practical course as per the schedule fixed by the college(s). The scheme of question paper for theory and practical sessional examinations is given in the table. The average marks of two sessional exams shall be computed for internal assessment as per the requirements given in tables.

12. Promotion and award of grades

A student shall be declared PASS and eligible for getting grade in a course of M.Pharm. programme if he/she secures at least 50% marks in that particular course including internal assessment.

13. Carry forward of marks

In case a student fails to secure the minimum 50% in any Theory or Practical course as specified in 12, then he/she shall reappear for the end semester examination of that course. However his/her marks of the Internal Assessment shall be carried over and he/she shall be entitled for grade obtained by him/her on passing.

14. Improvement of internal assessment

A student shall have the opportunity to improve his/her performance only once in the sessional exam component of the internal assessment. The re-conduct of the sessional exam shall be completed before the commencement of next end semester theory examinations.

15. Reexamination of end semester examinations

Reexamination of end semester examination shall be conducted as per the schedule given in table 29. The exact dates of examinations shall be notified from time to time.

Table - 29: Tentative schedule of end semester examinations

Semester	For Regular Candidates	For Failed Candidates
I and III	November / December	May / June
II and IV	May / June	November / December

16. Allowed to keep terms (ATKT):

No student shall be admitted to any examination unless he/she fulfills the norms given in 6. ATKT rules are applicable as follows:

A student shall be eligible to carry forward all the courses of I and II semesters till the III semester examinations. However, he/she shall not be eligible to attend the courses of IV semester until all the courses of I, II and III semesters are successfully completed.

A student shall be eligible to get his/her CGPA upon successful completion of the courses of I to IV semesters within the stipulated time period as per the norms.

Note: Grade AB should be considered as failed and treated as one head for deciding ATKT. Such rules are also applicable for those students who fail to register for examination(s) of any course in any semester.

17. Grading of performances

17.1. Letter grades and grade points allocations:

Based on the performances, each student shall be awarded a final letter grade at the end of the semester for each course. The letter grades and their corresponding grade points are given in Table - 30.

Table – 30: Letter grades and grade points equivalent to Percentage of marks and performances

Percentage of Marks Obtained	Letter Grade	Grade Point	Performance
90.00 – 100	O	10	Outstanding
80.00 – 89.99	A	9	Excellent
70.00 – 79.99	B	8	Good
60.00 – 69.99	C	7	Fair
50.00 – 59.99	D	6	Average
Less than 50	F	0	Fail
Absent	AB	0	Fail

A learner who remains absent for any end semester examination shall be assigned a letter grade of AB and a corresponding grade point of zero. He/she should reappear for the said evaluation/examination in due course.

18. The Semester grade point average (SGPA)

The performance of a student in a semester is indicated by a number called 'Semester Grade Point Average' (SGPA). The SGPA is the weighted average of the grade points obtained in all the courses by the student during the semester. For example, if a student takes five courses (Theory/Practical) in a semester with credits C₁, C₂, C₃ and C₄ and the student's grade points in these courses are G₁, G₂, G₃ and G₄, respectively, and then students' SGPA is equal to:

$$SGPA = \frac{C_1G_1 + C_2G_2 + C_3G_3 + C_4G_4}{C_1 + C_2 + C_3 + C_4}$$

The SGPA is calculated to two decimal points. It should be noted that, the SGPA for any semester shall take into consideration the F and ABS grade awarded in that semester. For example if a learner has a F or ABS grade in course 4, the SGPA shall then be computed as:

$$SGPA = \frac{C_1G_1 + C_2G_2 + C_3G_3 + C_4 \text{ ZERO}}{C_1 + C_2 + C_3 + C_4}$$

19. Cumulative Grade Point Average (CGPA)

The CGPA is calculated with the SGPA of all the IV semesters to two decimal points and is indicated in final grade report card/final transcript showing the grades of all IV semesters and their courses. The CGPA shall reflect the failed status in case of F grade(s), till the course(s) is/are passed. When the course(s) is/are passed by obtaining a pass grade on subsequent examination(s) the CGPA

shall only reflect the new grade and not the fail grades earned earlier. The CGPA is calculated as:

$$\text{CGPA} = \frac{C_1S_1 + C_2S_2 + C_3S_3 + C_4S_4}{C_1 + C_2 + C_3 + C_4}$$

where C_1, C_2, C_3, \dots is the total number of credits for semester I, II, III, \dots and S_1, S_2, S_3, \dots is the SGPA of semester I, II, III, \dots .

20. Declaration of class

The class shall be awarded on the basis of CGPA as follows:

First Class with Distinction	= CGPA of 7.50 and above
First Class	= CGPA of 6.00 to 7.49
Second Class	= CGPA of 5.00 to 5.99

21. Project work

All the students shall undertake a project under the supervision of a teacher in Semester III to IV and submit a report. 4 copies of the project report shall be submitted (typed & bound copy not less than 75 pages).

The internal and external examiner appointed by the University shall evaluate the project at the time of the Practical examinations of other semester(s). The projects shall be evaluated as per the criteria given below.

Evaluation of Dissertation Book:

Objective(s) of the work done	50 Marks
Methodology adopted	150 Marks
Results and Discussions	250 Marks
Conclusions and Outcomes	50 Marks

Total	500 Marks
-------	-----------

Evaluation of Presentation:

Presentation of work	100 Marks
Communication skills	50 Marks
Question and answer skills	100 Marks

Total	250 Marks
-------	-----------

22. Award of Ranks

Ranks and Medals shall be awarded on the basis of final CGPA. However, candidates who fail in one or more courses during the M.Pharm program shall not be eligible for award of ranks. Moreover, the candidates should have completed the M. Pharm program in minimum prescribed number of years, (two years) for the award of Ranks.

23. Award of degree

Candidates who fulfill the requirements mentioned above shall be eligible for award of degree during the ensuing convocation.

24. Duration for completion of the program of study

The duration for the completion of the program shall be fixed as double the actual duration of the program and the students have to pass within the said period, otherwise they have to get fresh Registration.

25. Revaluation I Retotaling of answer papers

There is no provision for revaluation of the answer papers in any examination. However, the candidates can apply for retotaling by paying prescribed fee.

26. Re-admission after break of study

Candidate who seeks re-admission to the program after break of study has to get the approval from the university by paying a condonation fee.

INDUSTRIALPHARMACY(MIP)
MODERN PHARMACEUTICAL ANALYTICAL TECHNIQUES
(MIP 101T)

Scope

This subject deals with various advanced analytical instrumental techniques for identification, characterization and quantification of drugs. Instruments dealt are NMR, Mass spectrometer, IR, HPLC, GC etc.

Objectives

After completion of course student is able to know,

- The analysis of various drugs in single and combination dosage forms
- Theoretical and practical skills of the instruments

THEORY

60 HOURS

1. UV-Visible spectroscopy: Introduction, Theory, Laws, 11 Hrs
Instrumentation associated with UV-Visible spectroscopy, Choice of solvents and solvent effect and Applications of UV-Visible spectroscopy.

IR spectroscopy: Theory, Modes of Molecular vibrations, Sample handling, Instrumentation of Dispersive and Fourier - Transform IR Spectrometer, Factors affecting vibrational frequencies and Applications of IR spectroscopy

Spectrofluorimetry: Theory of Fluorescence, Factors affecting fluorescence, Quenchers, Instrumentation and Applications of fluorescence spectrophotometer.

Flame emission spectroscopy and Atomic absorption spectroscopy: Principle, Instrumentation, Interferences and Applications.

- 2 NMR spectroscopy: Quantum numbers and their role in NMR, 11 Hrs
Principle, Instrumentation, Solvent requirement in NMR, Relaxation process, NMR signals in various compounds, Chemical shift, Factors influencing chemical shift, Spin-Spin coupling, Coupling constant, Nuclear magnetic double resonance, Brief outline of principles of FT-NMR and ¹³C NMR. Applications of NMR spectroscopy.

3 Mass Spectroscopy: Principle, Theory, Instrumentation of Mass Spectroscopy, Different types of ionization like electron impact, chemical, field, FAB and MALDI, APCI, ESI, APPI Analyzers of Quadrupole and Time of Flight, Mass fragmentation and its rules, Meta stable ions, Isotopic peaks and Applications of Mass spectroscopy 11 Hrs

4 Chromatography: Principle, apparatus, instrumentation, chromatographic parameters, factors affecting resolution and applications of the following: 11 Hrs
a) Paper chromatography b) Thin Layer chromatography
c) Ion exchange chromatography d) Column chromatography
e) Gas chromatography f) High Performance Liquid chromatography
g) Affinity chromatography

5 Electrophoresis: Principle, Instrumentation, Working conditions, factors affecting separation and applications of the following: 11 Hrs
a) Paper electrophoresis b) Gel electrophoresis c) Capillary electrophoresis d) Zone electrophoresis e) Moving boundary electrophoresis f) Iso electric focusing

X ray Crystallography: Production of X rays, Different X ray methods, Bragg's law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of X-ray diffraction.

6. Immunological Assays: Radioimmunity assay (RIA), ELISA (Theory & practical) and knowledge on Bioluminescence assays. 5 Hrs

REFERENCES

1. Spectrometric Identification of Organic compounds - Robert M Silverstein, 6th edition, John Wiley & Sons, 2004.
2. Principles of Instrumental Analysis - Douglas A Skoog, F. James Holler, Timothy A. Nieman, 5th edition, Eastern press, Bangalore, 1998.
3. Instrumental methods of analysis - Willards, 7th edition, CBS publishers.
4. Practical Pharmaceutical Chemistry - Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.
5. Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.
6. Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.
7. Pharmaceutical Analysis- Modern methods - Part B - J W Munson, Volume 11, Marcel Dekker Series

**PHARMACEUTICAL FORMULATION DEVELOPMENT
(MIP 102T)**

Scope

This course is designed to impart knowledge and skills necessary to train the students on par with the routine of Industrial activities in R&D and F&D.

Objectives

On completion of this course it is expected that students will be able to understand-

- The scheduled activities in a Pharmaceutical firm.
- The pre formulation studies of pilot batches of pharmaceutical industry.
- The significance of dissolution and product stability .

THEORY

60 Hrs

1. Preformulation Studies: Molecular optimization of APIs (drug substances), crystal morphology and variations, powder flow, structure modification, drug-excipient compatibility studies, methods of determination. 12 Hrs
2. Formulation Additives: Study of different formulation additives, factors influencing their incorporation, role of formulation development and processing, new developments in excipient science. Design of experiments - factorial design for product and process development. 12 Hrs
3. Solubility: Importance, experimental determination, phase-solubility analysis, pH-solubility profile, solubility techniques to improve solubility and utilization of analytical methods - cosolvency, salt formation, complexation, solid dispersion, micellar solubilization and hydrotropy. 12 Hrs
4. Dissolution: Theories, mechanisms of dissolution, in-vitro dissolution testing models - sink and non-sink. Factors influencing dissolution and intrinsic dissolution studies. Dissolution test apparatus - designs, dissolution testing for conventional and controlled release products. Data handling and correction factor. Biorelevant media, in-vitro and in-vivo correlations, levels of correlations. 12 Hrs

5. Product Stability: Degradation kinetics, mechanisms, stability testing of drugs and pharmaceuticals, factors influencing-media effects and pH effects, accelerated stability studies, interpretation of kinetic data (API & tablets). Solid state stability and shelf life assignment. Stability protocols, reports and ICH guidelines.

REFERENCES

1. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy, 3rd ed., Varghese Publishers, Mumbai 1991.
2. Sinko PJ. Martin's physical pharmacy and pharmaceutical sciences, 5th ed., B.I. Publications Pvt. Ltd, Noida, 2006.
3. Lieberman HA, Lachman L, Schwartz JB. Pharmaceutical dosage forms: tablets Vol. I-III, 2nd ed., CBS Publishers & distributors, New Delhi, 2005.
4. Connors KA. A Text book of pharmaceutical analysis Wells JI. Pharmaceutical preformulation: The physicochemical properties of drug substances. Ellis Horwood Ltd., England, 1998.
5. Yalkowsky SH. Techniques of solubilization of drugs. Vol-12. Marcel Dekker Inc., New York, 1981
6. Dressman J, Kramer J. Pharmaceutical dissolution testing. Saurah printer pvt. Ltd., New Delhi, 2005.
7. Sethi PD. Quantitative analysis of drugs in pharmaceutical formulations, 3rd ed., CBS publications, New Delhi, 2008.
8. Carstensen JT, Rhodes CT. Drug stability principles and practices, 3rd ed., CBS Publishers & distributors, New Delhi, 2005.
9. Yoshioka S, Stella VJ. Stability of drugs and dosage forms, Springer (India) Pvt. Ltd., New Delhi, 2006.
10. Banker GS, Rhodes CT. Modern Pharmaceutics, 4th ed., Marcel Dekker Inc, New York, 2005.
11. W. Grimm - Stability testing of drug products.
12. Mazzo DJ. International stability testing. Eastern Press Pvt. Ltd., Bangalore, 1999.
13. Beckett AH, Stenlake JB. Practical pharmaceutical chemistry, Part I & II., 4th ed., CBS Publishers & distributors, New Delhi, 2004.
14. Indian Pharmacopoeia. Controller of Publication. Delhi, 1996.
15. British Pharmacopoeia. British Pharmacopoeia Commission Office, London, 2008.
16. United States Pharmacopoeia. United States Pharmacopoeial Convention, Inc, USA, 2003.
17. Encyclopaedia of Pharm. Technology, Vol I - III.
18. Wells J. I. Pharmaceutical Preformulation : The physicochemical properties of drug substances, Ellis Horwood Ltd. England, 1988.

NOVEL DRUG DELIVERY SYSTEMS
(MIP 103T)

Scope

This course is designed to impart knowledge and skills necessary to train the students in the area of novel drug delivery systems.

Objective

On completion of this course it is expected that students will be able to understand,

- The need, concept, design and evaluation of various customized, sustained and controlled release dosage forms.
- To formulate and evaluate various novel drug delivery systems

THEORY

60 Hrs

1. Concept & Models for NDDS: Classification of rate controlled drug delivery systems (DDS), rate programmed release, activation modulated & feedback regulated DDS, effect of system parameters in controlled drug delivery, computation of desired release rate and dose for controlled release DDS, pharmacokinetic design for DDS - intermittent, zero order & first order release. 12 Hrs

Carriers for Drug Delivery: Polymers / co-polymers- introduction, classification, characterization, polymerization techniques, application in CDDS / NDDS, biodegradable & natural polymers.

2. Study of Various DDS: Concepts, design, formulation & evaluation of controlled release oral DDS, Mucoadhesive DDS (buccal, nasal, pulmonary) Pulsatile, colon specific, liquid sustained release systems, Ocular delivery systems 12 Hrs
3. Transdermal Drug Delivery Systems: Theory, design, formulation & evaluation including iontophoresis and other latest developments in skin delivery systems. 08 Hrs
4. Sub Micron Cosmeceuticals: Biology, formulation science and evaluation of various cosmetics for skin, hair, nail, eye etc and it's regulatory aspects. 04 Hrs

- 5 Targeted Drug Delivery Systems: Importance, concept, 12
biological process and events involved in drug targeting, design, Hrs
formulation & evaluation, methods in drug targeting -
nanoparticles, liposomes, niosomes, pharmacosomes, resealed
erythrocytes, microspheres, magnetic microspheres. Specialized
pharmaceutical emulsions - multiple emulsions, micro-emulsions.
- 6 Protein / Peptide Drug Delivery Systems: Concepts, delivery
techniques, formulation, stability testing, causes of protein
destabilization, stabilization methods.
- 7 Biotechnology in Drug Delivery Systems: Brief review of 06
major areas-recombinant DNA technology, monoclonal antibodies, Hrs
gene therapy.
- 8 New trends for Personalized Medicine: Introduction, Definition, 06
Pharmacogenetics, Categories of Patients for Personalized Hrs
Medicines: Customized drug delivery systems, Bioelectronic
Medicines, 3D printing of pharmaceuticals, Telepharmacy.

REFERENCES

1. Novel Drug Delivery System, Y.W. Chein, Vol 50, Marcel Dekker, NY.
2. Controlled Drug Delivery Systems, Robinson, Vol 29, Marcel Dekker, NY.
3. Transdermal Controlled Systemic Medications, YW Chein, Vol 31, Marcel
Dekker, NY.
4. Bioadhesive DDS, E. Mathiowitz, Vol 98, Marcel Dekker, NY.
5. Nasal System Drug Delivery, K.S.E. Su, Vol 39, Marcel Dekker, NY.
6. Drug Delivery Devices, Vol 32, P Tyle Marcel Dekker, NY.
7. Polymers for Controlled Drug Delivery, P.J. Tarcha, CRC Press.
8. Pharmaceutical Biotechnology, Vyas, CBS, Delhi.
9. Biotechnology of Industrial Antibiotics, E.J. Vandamme, Marcel Dekker,
NY.
10. Protein Formulation & Delivery, E.J. McNally, Vol 99, Marcel Dekker, NY.
11. Drug Targeting, M.H. Rubinstein, John Wiley, NY.

INTELLECTUAL PROPERTY RIGHTS
(MIP 104T)

Scope

This course is designed to impart knowledge and skills necessary to train the students to be on par with the routine of Industrial activities in drug regulatory affairs

Objectives

On completion of this course it is expected that students will be able to understand,

- Assist in Regulatory Audit process.
- Establish regulatory guidelines for drug and drug products
- The Regulatory requirements for contract research organization

THEORY

60 Hrs

- | | | |
|----|---|--------|
| 1. | Definition, Need for patenting, Types of Patents, Conditions to be satisfied by an Invention to be patentable, Introduction to patent search. Parts of patents. Filing of patents. The essential elements of patent; Guidelines for preparation of laboratory note book, Non-obviousness in Patent. | 12 Hrs |
| 2 | Role of GATT, TRIPS, and WIPO | 12 Hrs |
| 3 | Brief introduction to Trademark protection and WHO Patents. IPR's and its types, Major bodies regulating Indian Pharmaceutical sector. | 12 Hrs |
| 4 | Brief introduction to CDSCO. WHO, USFDA, EMEA, TGA, MHRA, MCC, ANVISA | 12 Hrs |
| 5 | Regulatory requirements for contract research organization. Regulations for Biosimilars. | 12 Hrs |

REFERENCES :

1. Pharmaceutical Process Validation: By Fra R. Berry and Robert A. Nash, Vol 57, 2nd Edition
2. Applied Production and Operation Management By Evans, Anderson and Williams
3. GMP for pharmaceuticals Material Management by K.K. Ahuja Published by CBS publishers
4. ISO 9000-Norms and explanations
5. GMP for pharmaceuticals- Willing S.H. Marcel and Dekker

INDUSTRIAL PHARMACY PRACTICAL - I
(MIP 105P)

1. Analysis of pharmacopoeial compounds and their formulations by UV Vis spectrophotometer
2. Simultaneous estimation of multi component containing formulations by UV spectrophotometry
3. Experiments based on HPLC / GC
4. Estimation of riboflavin/quinine sulphate by fluorimetry
5. Estimation of sodium/potassium by flame photometry
6. Effect of surfactants on the solubility of drugs.
7. Effect of pH on the solubility of drugs.
8. Stability testing of solution and solid dosage forms for photo degradation..
9. Stability studies of drugs in dosage forms at 25 °C, 60% RH and 40 °C, 75% RH.
10. Compatibility evaluation of drugs and excipients (DSC & FTIR).
11. Preparation and evaluation of different polymeric membranes.
12. Formulation and evaluation of sustained release oral matrix tablet/ oral reservoir system.
13. Formulation and evaluation of microspheres / microcapsules.
14. Formulation and evaluation of transdermal drug delivery systems.
15. Design and evaluation of face wash, body- wash, creams, lotions, shampoo, toothpaste, lipstick.
16. Electrophoresis of protein solution.
17. Preparation and evaluation of Liposome delivery system.

ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS
(MIP 201T)

Scope

This course is designed to impart knowledge and skills necessary for dose calculations, dose adjustments and to apply Biopharmaceutics theories in practical problem solving.

Objectives

On completion of this course it is expected that students will be able to understand,

- The basic concepts in Biopharmaceutics and pharmacokinetics.
- The use of raw data and derive the pharmacokinetic models and parameters the best describe the process of drug absorption, distribution, metabolism and elimination.
- To critically evaluate Biopharmaceutics studies involving drug product equivalency.
- To design and evaluate dosage regimens of the drugs using pharmacokinetic and biopharmaceutic parameters.

THEORY

60 Hrs

1. Drug Absorption From The Gastrointestinal Tract: 12 Hrs
Gastrointestinal tract, Mechanism of drug absorption, Factors affecting, pH-partition theory, Formulation and physicochemical factors: Dissolution rate, Dissolution process, Noyes-Whitney equation and drug dissolution, Factors affecting the dissolution rate. Gastrointestinal absorption: role of the dosage form: Solution (elixir, syrup and solution) as a dosage form, Suspension as a dosage form, Capsule as a dosage form, Tablet as a dosage form, Dissolution methods, Formulation and processing factors, Correlation of in vivo data with in vitro dissolution data. Transport model: Permeability-Solubility-Charge State and the pH Partition Hypothesis, Properties of the Gastrointestinal Tract (GIT), pH Microclimate Intracellular pH Environment, Tight-Junction Complex. Solubility: Experimental methods. Permeability: In-vitro, in-situ and In-vivo methods.
2. Biopharmaceutic Considerations in Drug Product Design and In Vitro Drug Product Performance: 12 Hrs
Introduction, Biopharmaceutic Factors Affecting Drug Bioavailability, Rate-Limiting Steps in Drug Absorption, Physicochemical Nature of the

Drug Formulation Factors Affecting Drug Product Performance, In Vitro: Dissolution and Drug Release Testing, Compendial Methods of Dissolution, Alternative Methods of Dissolution Testing, Meeting Dissolution Requirements, Problems of Variable Control in Dissolution Testing Performance of Drug Products: In Vitro-In Vivo Correlation, Dissolution Profile Comparisons, Drug Product Stability, Considerations in the Design of a Drug Product.

- 3 Pharmacokinetics: Basic considerations, Pharmacokinetic models, Compartment modeling: One compartment model- IV bolus, IV infusion, Extra-vascular; Multi Compartment model: Two compartment - model in brief, Non-Linear Pharmacokinetics: Cause of non-linearity, Michaelis - Menten equation, Estimation K_{max} and V_{max} . Drug interactions: Introduction, The effect of protein-binding interactions, The effect of tissue-binding interactions, Cytochrome P450-based drug interactions, Drug interactions linked to transporters. 12 Hrs

- 4 Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: Drug Product Performance, Purpose of Bioavailability Studies, Relative and Absolute Availability, , Methods for Assessing Bioavailability, Bioequivalence Studies, Design and Evaluation of Bioequivalence Studies, Study Designs, Crossover Study Designs, Evaluation of the Data, Bioequivalence Example, Study Submission and Drug Review Process, The Biopharmaceutics Classification System, Generic Biologics (Biosimilar Drug Products), Clinical Significance of Bioequivalence Studies, Special Concerns in Bioavailability and Bioequivalence Studies, Generic Substitution. 12 Hrs

- 5 Application of Pharmacokinetics: Modified-Release Drug Products, Targeted Drug Delivery Systems and Biotechnological Products. Relationship between Pharmacokinetics including Pharmacodynamics: Generation of a pharmacokinetic-pharmacodynamic (PKPD) equation, Pharmacokinetic and pharmacodynamic, interactions. Pharmacokinetics and pharmacodynamics of biotechnology drugs: Introduction, Proteins and peptides, Monoclonal antibodies, Oligonucleotides, Vaccines (immunotherapy), Gene therapies. 12 Hrs

REFERENCES

1. Biopharmaceutics and Clinical Pharmacokinetics by Milo Gibaldi, 4th edition, Philadelphia, Lea and Febiger, 1991
2. Biopharmaceutics and Pharmacokinetics, A Treatise, D .M. Brahmankar and Sunil B.J aiswal., Vallab Prakashan, Pitampura, Delhi
3. Applied Biopharmaceutics and Pharmacokinetics by Shargel. Land YuABC, 2nd edition, Connecticut Appleton Century Crofts, 1985
4. Textbook of Biopharmaceutics and Pharmacokinetics, Dr. Shobha Rani R. Hiremath, Prism Book
5. Pharmacokinetics by Milo Gibaldi and D. Perrier, 2nd edition, Marcel Dekker Inc., New York, 1982
6. Current Concepts in Pharmaceutical Sciences: Biopharmaceutics, Swarbrick. J, Lea and Febiger, Philadelphia, 1970
7. Clinical Pharmacokinetics, Concepts and Applications 3rd edition by Malcolm Rowland and Thom~ N. Tozer, Lea and Febiger, Philadelphia, 1995
8. Dissolution, Bioavailability and Bioequivalence, Abdou. H.M, Mack Publishing Company, Pennsylvania 1989
9. Biopharmaceutics and Clinical Pharmacokinetics, An Introduction, 4th edition, revised and expanded by Robert. E. Notari, Marcel Dekker Inc, New York and Basel, 1987.
10. Biopharmaceutics and Relevant Pharmacokinetics by John. G Wagner and M.Pemarowski, 1st edition, Drug Intelligence Publications, Hamilton, Illinois, 1971.
11. Encyclopedia of Pharmaceutical Technology, Vol 13, James Swarbrick, James. G.Boylan, Marcel Dekker Inc, New York, 1996.
12. Basic Pharmacokinetics, 1 st edition, Sunil S Jambhekar and Philip J Breen, pharmaceutical press, RPS Publishing, 2009.
13. Absorption and Drug Development- Solubility, Permeability, and Charge State, Alex Avdeef, John Wiley & Sons, Inc, 2003.

SCALE UP AND TECHNOLOGY TRANSFER (MIP 202T)

Scope

This course is designed to impart knowledge and skills necessary to train the students to be on scale up, technology transfer process and industrial safety issues.

Objectives:

On completion of this course it is expected that students will be able to understand,

- Manage the scale up process in pharmaceutical industry.
- Assist in technology transfer.
- To establish safety guidelines, which prevent industrial hazards.

THEORY

60 Hrs

1. Pilot plant design: Basic requirements for design, facility, equipment selection, for tablets, capsules, liquid orals, parenteral and semisolid preparations. 12 Hrs

Scale up: Importance, Technology transfer from R & D to pilot plant to plant scale, process scale up for tablets, capsules, liquid orals, semisolids, parenteral, NDDS products – stress on formula, equipments, product uniformity, stability, raw materials, physical layout, input, in-process and finished product specifications, problems encountered during transfer of technology

- 2 Validation: General concepts, types, procedures & protocols, documentation, VMF. Analytical method validation, cleaning validation and vendor qualification. 12 Hrs
- 3 Equipment Qualification: Importance, IQ, OQ, PQ for equipments – autoclave, DHS, membrane filter, rapid mixer granulator, cone blender, FBD, tablet compression machine, liquid filling and sealing machine. Aseptic room validation. 12 Hrs
- 4 Process validation: Importance, validation of mixing, granulation, drying, compression, tablet coating, liquid filling and sealing, sterilization, water process systems, environmental control. 12 Hrs

- 5 Industrial safety: Hazards - fire, mechanical, electrical, 12 chemical and pharmaceutical, Monitoring & prevention systems, Hrs industrial effluent testing & treatment. Control of environmental pollution.

REFERENCES

1. Pharmaceutical process validation, JR Berry, Nash, Vol 57, Marcel Dekker, NY.
2. Pharmaceutical Production facilities, design and applications, by GC Cole, Taylor and Francis.
3. Pharmaceutical project management, T.Kennedy, Vol 86, Marcel Dekker, NY.
4. The theory & Practice of Industrial Pharmacy, L.Lachman, H.A.Lieberman, Varghese Publ. Bombay.
5. Tablet machine instruments in pharmaceuticals, PR Watt, John Wiloy.
6. Pharmaceutical dosage forms, Tablets, Vol 1, 2, 3 by Lachman, Lieberman, Marcel Dekker, NY.
7. Pharmaceutical dosage forms, Parental medications, Vol 1, 2 by K.E. Avis, Marcel Dekker, NY.
8. Dispersed system Vol 1, 2, 3 by Lachman, Lieberman, Marcel Dekker, NY.
9. Subrahmanyam, CVS, Pharmaceutical production and Management, 2007, Vallabh Prakashan, Dehli.

PHARMACEUTICAL PRODUCTION TECHNOLOGY
(MIP 203T)

Scope

This course is designed to impart knowledge and skills necessary to train the students to be on par with the routine of Industrial activities in Production

Objectives

On completion of this course it is expected that students will be able to understand,

- Handle the scheduled activities in a Pharmaceutical firm.
- Manage the production of large batches of pharmaceutical formulations.

THEORY

60 Hrs

- Improved Tablet Production: Tablet production process, unit operation improvements, granulation and pelletization equipments, continuous and batch mixing, rapid mixing granulators, rota granulators, spheronizers and marumerisers, and other specialized granulation and drying equipments. Problems encountered. 12 Hrs
- Coating Technology: Process, equipments, particle coating, fluidized bed coating, application techniques. Problems encountered. 12 Hrs
1. Parenteral Production: Area planning & environmental control, wall and floor treatment, fixtures and machineries, change rooms, personnel flow, utilities & utilities equipment location, engineering and maintenance. 12 Hrs
2. Lyophilization & Spray drying Technology: Principles, process, freeze-drying and spray drying equipments. 12 Hrs
3. Capsule Production: Production process, improved capsule manufacturing and filling machines for hard and soft gelatin capsules. Layout and problems encountered. 12 Hrs
- Disperse Systems Production: Production processes, applications of mixers, mills, disperse equipments including fine solids dispersion, problems encountered.

Packaging Technology: Types of packaging materials, machinery, labeling, package printing for different dosage forms.

- 5 Air Handling Systems: Study of AHUs, humidity & temperature control, air filtration systems, dust collectors. Water Treatment Process: Techniques and maintenance - RO, DM, ultra - filtration, WFI. 12 Hrs

REFERENCES

1. The Theory & Practice of Industrial Pharmacy, L. Lachman, Varghese Publ, Bombay.
2. Modern Pharmaceutics by Banker, Vol 72, Marcel Dekker, NY.
3. Pharmaceutical Dosage Forms, Vol 1, 2, 3 by Lachman, Lieberman, Marcel Dekker, NY.
4. Pharmaceutical Dosage Forms, Parenteral medications, Vol 1, 2 by K.E. Avis, Marcel Dekker, NY.
5. Pharmaceutical Production Facilities, design and applications, by G.C. Cole, Taylor and Francis.
6. Dispersed System Vol 1, 2, 3 by Lachman, Lieberman, Marcel Dekker, NY.
7. Product design and testing of polymeric materials by N.P. Chezerisionoff.
8. Pharmaceutical Project Management, T.Kennedy, Vol 86, Marcel Dekker, NY.
9. Packaging Pharmaceutical and Health Care; H.Lockhard.
10. Quality Control of Packaging Materials in Pharmaceutical Industry, Kharburn, Marcel Dekker, NY.
11. Freeze drying / Lyophilization of Pharmaceuticals & Biological Products, L. Ray, Vol 96, Marcel Dekker, NY.
12. Tablet Machine Instrumentation In Pharmaceuticals, PR Watt, Ellis Horwoods, UK.

ENTREPRENEURSHIP MANAGEMENT
(MIP 204T)

Scope

This course is designed to impart knowledge and skills necessary to train the students on entrepreneurship management.

Objectives:

On completion of this course it is expected that students will be able to understand,

- The Role of enterprise in national and global economy
- Dynamics of motivation and concepts of entrepreneurship
- Demands and challenges of Growth Strategies And Networking

THEORY

60 Hrs

1. **Conceptual Frame Work:** Concept need and process in entrepreneurship development. Role of enterprise in national and global economy. Types of enterprise - Merits and Demerits. Government policies and schemes for enterprise development. Institutional support in enterprise development and management. 12 Hrs
2. **Entrepreneur:** Entrepreneurial motivation - dynamics of motivation. Entrepreneurial competency -Concepts. Developing Entrepreneurial competencies - requirements and understanding the process of entrepreneurship development, self-awareness, interpersonal skills, creativity, assertiveness, achievement, factors affecting entrepreneur role. 12 Hrs
3. **Launching And Organising An Enterprise:** Environment scanning - Information, sources, schemes of assistance, problems. Enterprise selection, market assessment, enterprise feasibility study, SWOT Analysis. Resource mobilisation - finance, technology, raw material, site and manpower. Costing and marketing management and quality control. Feedback, monitoring and evaluation. 12 Hrs
4. **Growth Strategies And Networking:** Performance appraisal and assessment. Profitability and control measures, demands and challenges. Need for diversification. Future Growth - Techniques of expansion and diversification, vision strategies. Concept and dynamics. Methods, Joint venture, co-ordination and feasibility study. 12 Hrs

INDUSTRIAL PHARMACY PRACTICAL - II
(MIP 205P)

1. Improvement of dissolution characteristics of slightly soluble drug by Solid dispersion technique.
2. Comparison of dissolution of two different marketed products /brands
3. Protein binding studies of a highly protein bound drug & poorly protein bound drug
4. Bioavailability studies of Paracetamol (Animal).
5. Pharmacokinetic and IVIVC data analysis by WinnolineR software
6. In vitro cell studies for permeability and metabolism
7. Formulation and evaluation of tablets
8. Formulation and evaluation of capsules
9. Formulation and evaluation of injections
10. Formulation and evaluation of emulsion
11. Formulation and evaluation of suspension.
12. Formulation and evaluation of enteric coating tablets.
13. Preparation and evaluation of a freeze dried formulation.
14. Preparation and evaluation of a spray dried formulation.

PHARMACEUTICAL REGULATORY AFFAIRS (MRA)

GOOD REGULATORY PRACTICES (MRA 101T)

Scope

This course is designed to impart fundamental knowledge on various Good Regulatory Practices viz., cGMP, GLP, GALP and GDP for Pharmaceuticals, Cosmetics, Food & Nutraceuticals, Medical devices, In-vitro Diagnostic Medical Devices (IVDs) and biological products and understand the rationale behind these requirements and will propose ways and means of complying with them.

Objectives

At completion of this course it is expected that students will be able to understand,

- The key regulatory and compliance elements with respect to Good Manufacturing Practices, Good Laboratory Practices, Good Automated Laboratory Practices and Good Documentation Practices.
- Prepare and implement the check lists and SOPs for various Good Regulatory Practices
- Implement Good Regulatory Practices in the Healthcare and related Industries
- Prepare for the readiness and conduct of audits and inspections.

THEORY

60 Hrs

1. Current Good Manufacturing Practices: Introduction, US cGMP Part 210 and Part 211.EC Principles of GMP (Directive 91/356/EEC) Article 6 to Article 14 and WHO cGMP guidelines GAMP-5; Medical device and IVDs Global Harmonization Task Force(GHTF) Guidance docs. 12 Hrs
2. Good Laboratory Practices: Introduction, USFDA GLP Regulations (Subpart A to Subpart K), Controlling the GLP inspection process, Documentation, Audit, goals of Laboratory Quality Audit, Audit tools, Future of GLP regulations, relevant ISO and Quality Council of India(QCI) Standards 12 Hrs
3. Good Automated Laboratory Practices: Introduction to GALP, Principles of GALP, GALP Requirements, SOPs of GALP, Training Documentation, 21 CFR Part 11, General check list of 21CFR Part 11, Software Evaluation checklist, relevant ISO and QCI Standards. 12 Hrs

- 4 Good Distribution Practices: Introduction to GDP, Legal GDP 12
 requirements put worldwide, Principles, Personnel, Hrs
 Documentation, Premises and Equipment, Deliveries to
 Customers, Returns, Self-Inspection, Provision of information,
 Stability testing principles, WHO. GDP, USP GDP (Supply chain
 integrity), relevant CDSCO guidance and ISO standards
- 5 Quality management systems: Concept of Quality, Total Quality 12
 Management, Quality by design, Six Sigma concept, Out of Hrs
 Specifications (OOS), Change control. Validation: Types of
 Validation, Types of Qualification, Validation master plan (VMP),
 Analytical Method Validation. Validation of utilities, [Compressed
 air, steam, water systems, Heat Ventilation and Air conditioning
 (HVAC)]and Cleaning Validation. The International Conference on
 Harmonization (ICH) process, ICH guidelines to establish quality,
 safety and efficacy of drug substances and products, ISO 13485,
 Sch VIII and other relevant CDSCO regulatory guidance
 documents.

REFERENCES

1. Good Laboratory Practice Regulations, by Sandy Weinberg, Fourth Edition
 Drugs and the Pharmaceutical Sciences, Vol.168
2. Good Pharmaceutical Manufacturing practice, Rational and compliance by
 John Sharp, CRC Press
3. Establishing a cGMP Laboratory Audit System, A practical Guide by David
 M.Bleisner, Wiley Publication.
4. How to practice GLP by PP Sharma, Vandana Publications.
5. Laboratory Auditing for Quality and Regulatory compliance bu Donald
 C.Singer, Drugs and the Pharmaceutical Sciences, Vol.150.
6. Drugs & Cosmetics Act, Rules & Amendments

**DOCUMENTATION AND REGULATORY WRITING
(MRA 102T)**

Scope

This course is designed to impart fundamental knowledge on documentation and general principles involved in regulatory writing and submission to agencies.

Objectives

Upon completion of the course the student shall be able to,

- Know the various documents pertaining to drugs in pharmaceutical industry
- Understand the basics of regulatory compilation
- Create and assemble the regulation submission as per the requirements of agencies
- Follow up the submissions and post approval document requirements

THEORY

60 Hrs

1. Documentation in pharmaceutical industry: Exploratory Product Development Brief (EPDB) for Drug substance and Drug product, Product Development Plan (PDP), Product Development Report (PDR), Master Formula Record, Batch Manufacturing Record and its calculations, Batch Reconciliation, Batch Packaging Records, Print pack specifications, Distribution records, Certificate of Analysis (CoA), Site Master File and Drug Master Files (DMF). 12 Hrs
2. Dossier preparation and submission: Introduction and overview of dossiers, contents and organization of dossier, binders and sections, compilation and review of dossier. Paper submissions, overview and modules of CTD, electronic CTD submissions; Electronic submission: Planning electronic submission, requirements for submission, regulatory bindings and requirements, Tool and Technologies, electronic dossier submission process and validating the submission, Electronic Submission Gateway (ESG). Non eCTD electronic submissions (NeeS), Asian CTD formats (ACTD) submission. Organizing, process and validation of submission. Submission in Sugam system of CDSCO. 12 Hrs

- | | | |
|---|--|-----------|
| 3 | Audits: Introduction, Definition, Summary, Types of audits, GMP compliance audit, Audit policy, Internal and External Audits, Second Party Audits, External third party audits, Auditing strategies, Preparation and conducting audit, Auditing strategies, audit analysis, audit report, audit follow up. Auditing/inspection of manufacturing facilities by regulatory agencies. Timelines for audits/inspection. GHTF study group 4 guidance document. ISO 13485. | 12
Hrs |
| 4 | Inspections: Pre-approval inspections, Inspection of pharmaceutical manufacturers, Inspection of drug distribution channels, Quality systems requirements for national good manufacturing practice inspectorates, inspection report, model certificate of good manufacturing practices, Root cause analysis, Corrective and Preventive action (CAPA). | 12
Hrs |
| 5 | Product life cycle management: Prior Approval Supplement (PAS), Post Approval Changes [SUPAC], Changes Being Effected in 30 Days (CBE-30), Annual Report, Post marketing Reporting Requirements, Post approval Labeling Changes, Lifecycle Management, FDA Inspection and Enforcement, Establishment Inspection Report (EIR), Warning Letters, Recalls, Seizure and Injunctions. ISO Risk Management Standard | 12
Hrs |

REFERENCES

1. Compliance auditing for Pharmaceutical Manufacturers. Karen Ginsbury and Gil Bismuth, Interpharm/CRC, Boca Raton, London New York, Washington D.C.
2. Pharmaceutical Manufacturing Handbook, Regulations and Quality by Shayne Cox Gad. Wiley-Interscience, A John Wiley and sons, Inc., Publications.
3. Handbook of microbiological Quality control. Rosamund M. Baird, Norman A. Hodges, Stephen P. Denyar. CRC Press. 2000.
4. Laboratory auditing for quality and regulatory compliance. Donald C. Singer, Raluca-loana Stefan, Jacobus F. Van Staden. Taylor and Francis (2005).
5. Implementing Juran's Road Map for Quality Leadership: Benchmarks and Results, By Al Endres, Wiley, 2000
6. Understanding, Managing and Implementing Quality: Frameworks, Techniques and Cases, By Jiju Antony; David Preece, Routledge, 2002

7. Organizing for High Performance: Employee Involvement, TQM, Reengineering, and Knowledge Management in the Fortune 1000: The CEO Report By Edward E. Lawler; Susan Albers Mohrman; George Benson, Jossey-Bass, 2001
8. Corporate Culture and the Quality Organization By James W. Fairfield-Sonn, Quorum Books, 2001
9. The Quality Management Sourcebook: An International Guide to Materials and Resources By Christine Avery; Diane Zabel, Routledge, 1997
10. The Quality Toolbox, Second Edition, Nancy R. Tague, ASQ Publications
11. Juran's Quality Handbook, Sixth Edition, Joseph M. Juran and Joseph A. De Feo, ASQ Publications
12. Root Cause Analysis, The Core of Problem Solving and Corrective Action, Duke Okes, 2009, ASQ Publications
13. International Medical Device Regulators Forum (IMDRF) Medical Device Single Audit Program (MDSAP)

CLINICAL RESEARCH REGULATIONS (MRA 103T)

Scope

This course is designed to impart the fundamental knowledge on the clinical development process of drugs, pharmaceuticals and Medical Devices, phases and conduct of clinical trials and research, regulations and guidance governing the conduct of clinical research in India, USA and EU. It prepares the students to learn in detail on various laws, legislations and guidance related to safety, efficacy, ethical conduct and regulatory approval of clinical research.

Objectives

Upon completion of the course, the student shall be able to (know, do and appreciate)

- History, origin and ethics of clinical and biomedical research and evaluation
- Clinical drug, medical device development process and different types and phases of clinical trials
- Regulatory requirements and guidance for conduct of clinical trials and research

Theory

60 Hrs

1. Clinical Drug Development Process 12 Hrs
 - Different types of Clinical Studies
 - Phases of clinical trials, Clinical Trial protocol
 - Phase 0 studies
 - Phase I and subtype studies (single ascending, multiple ascending, dose escalation, methods, food effect studies, drug - drug interaction, PK end points)
 - Phase II studies (proof of concept or principle studies to establish efficacy)
 - Phase III studies (Multi ethnicity, global clinical trial, registration studies)
 - Phase IV studies (Post Marketing Studies; PSUR)
- Clinical Investigation and Evaluation of Medical Devices & IVDs
- Different Types of Studies
Key Concepts of Medical Device Clinical Evaluation
Key concepts of Clinical Investigation

- 2 Ethics in Clinical Research: 12 Hrs
- Historical Perspectives: Nuremberg Code, Thalidomide study , Nazis Trials, Tuskegee Syphilis Study, The Belmont Report, The declaration of Helsinki
 - Origin of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines.
 - The ethics of randomized clinical trials
 - The role of placebo in clinical trials
 - Ethics of clinical research in special population
 - Institutional Review Board/Independent Ethics Committee/Ethics Committee - composition, roles, responsibilities, review and approval process and ongoing monitoring of safety data
 - Data safety monitoring boards.
 - Responsibilities of sponsor, CRO, and investigator in ethical conduct of clinical research
 - Ethical principles governing informed consent process
 - Patient Information Sheet and Informed Consent Form
 - The informed consent process and documentation
- 3 Regulations governing Clinical Trials 12 Hrs
- India: Clinical Research regulations in India - Schedule Y & Medical Device Guidance
- USA: Regulations to conduct drug studies in USA (FDA)
- NDA 505(b)(1) of the FD&C Act (Application for approval of a new drug)
 - NDA 505(b)(2) of the FD&C Act (Application for approval of a new drug that relies, at least in part, on data not developed by the applicant)
 - ANDA 505(j) of the FD&C Act (Application for approval of a generic drug product)
 - FDA Guidance for Industry - Acceptance of Foreign Clinical Studies
 - FDA Clinical Trials Guidance Document: Good Clinical Practice
- EU: Clinical Research regulations in European Union (EMA)

- | | | |
|---|--|-----------|
| 4 | <p>Clinical Research Related Guidelines</p> <ul style="list-style-type: none"> - Good Clinical Practice Guidelines (ICH GCP E6) - Indian GCP Guidelines - ICMR Ethical Guidelines for Biomedical Research - CDSCO guidelines <p>GHTF study group 5 guidance documents</p> <p>Regulatory Guidance on Efficacy and Safety ICH Guidance's</p> <ul style="list-style-type: none"> - E4 - Dose Response Information to support Drug Registration - E7 - Studies in support of General Population: Geriatrics - E8 - General Considerations of Clinical Trials - E10 - Choice of Control Groups and Related Issues in Clinical Trials, - E 11 - Clinical Investigation of Medicinal Products in the Pediatric Population - General biostatistics principle applied in clinical research | 12
Hrs |
| 5 | <p>USA & EU Guidance</p> <p>USA: FDA Guidance</p> <ul style="list-style-type: none"> - CFR 21Part 50: Protection of Human Subjects - CFR 21Part 54: Financial Disclosure by Clinical Investigators - CFR 21Part 312: IND Application - CFR 21Part 314: Application for FDA Approval to Market a New Drug - CFR 21Part 320: Bioavailability and bioequivalence requirements - CFR 21Part 812: Investigational Device Exemptions - CFR 21Part 822: Post-market surveillance - FDA Safety Reporting Requirements for INDs and BA/BE Studies - FDA Med Watch - Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment <p>European Union: EMA Guidance</p> <ul style="list-style-type: none"> - EU Directives 2001 - EudraLex (EMA) Volume 3 - Scientific guidelines for medicinal products for human use - EU Annual Safety Report (ASR) - Volume 9A - Pharmacovigilance for Medicinal Products for Human Use - EU MDD with respect to clinical research - ISO 14155 | 12
Hrs |

REFERENCES

1. Clinical Trials and Human Research: A Practical Guide to Regulatory Compliance By Fay A. Rozovsky and Rodney K. Adams
2. HIPAA and Human Subjects Research: A Question and Answer Reference Guide By Mark Barnes, JD, LLM and Jennifer Kulynych, JD, PhD
3. Principles and Practices of Clinical Research, Second Edition Edited by John I. Gallin and Frederick P. Ognibene
4. Reviewing Clinical Trials: A Guide for the Ethics Committee; Johan PE Karlberg and Marjorie A Speers; Karlberg, Johan Petter Einar, Hong Kong.
5. International Pharmaceutical Product Registration: Aspects of Quality, Safety and Efficacy; Anthony C. Cartwright; Taylor & Francis Inc., USA.
6. New Drug Approval Process: The Global Challenge; Guarino, Richard A; Marcel Dekker Inc., NY.
7. FDA regulatory affairs: a guide for prescription drugs, medical devices, and biologics; Douglas J. Pisano, David Mantus; CRC Press, USA
8. Country Specific Guidelines from official websites.
9. Drugs & Cosmetics Act & Rules and Amendments

RECOMMENDED WEBSITES:

1. EU Clinical Research Directive 2001: <http://www.eortc.be/services/doc/clinical-eudirective-04-april-01.pdf>
2. Code of Federal Regulations, FDA: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm>
3. Guidelines of International Conference on Harmonization: <http://www.ich.org/products/guidelines.html>
4. Eudralex Guidelines: <http://www.gmpcompliance.info/euguide.htm>
5. FDA New Drug Application:
6. <http://www.fda.gov/regulatoryinformation/legislation/FederalFoodDrugsandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/ucm108125.htm>
7. Medicines and Healthcare products Regulatory Agency: <http://www.mhra.gov.uk>
8. Central Drugs Standard Control Organization Guidance for Industry: <http://cdsco.nic.in/CDSCO-GuidanceForIndustry.pdf>
9. ICMR Ethical Guidelines for Biomedical Research: http://icmr.nic.in/ethical_guidelines.pdf

REGULATIONS AND LEGISLATION FOR DRUGS & COSMETICS,
MEDICAL DEVICES, BIOLOGICALS & HERBALS, AND FOOD &
NUTRACEUTICALS IN INDIA AND INTELLECTUAL PROPERTY
RIGHTS
(MRA 104T)

Scope

This course is designed to impart fundamental knowledge on regulations and legislation in India w.r.t. Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals. It prepares the students for basic regulatory requirements in India of Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals. for manufacture, import & registration, export, sale, marketing authorization, clinical trials and intellectual property rights.

Objectives

Upon the completion of the course the student shall be able to:

- Know different Acts and guidelines that regulate Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals industry in India.
- Understand the approval process and regulatory requirements for Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals

THEORY

60 Hrs

1. Biologicals & Herbals, and Food & Nutraceuticals
Acts and Rules (with latest amendments):

12
Hrs

1. Drugs and Cosmetics Act 1940 and Rules 1945: DPCO and NPPA
2. Other relevant provisions (rules schedules and guidelines for approval of Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals in India

Other relevant Acts: Narcotics Drugs and Psychotropic Substances Act; Medicinal and Toilet Preparations (Excise Duties) Act, 1955; Pharmacy Act, 1948; Drugs and Magic Remedies (Objectionable Advertisements) Act, 1955; Prevention of Cruelty to Animals Act.

- 2 Regulatory requirements and approval procedures for Drugs & Cosmetics Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals 12 Hrs

CDSCO (Central Drug Standard Control Organization) and State Licensing Authority: Organization, Responsibilities

- Rules, regulations, guidelines and standards for regulatory filing of Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals
- Format and contents of Regulatory dossier filing

Clinical trial/ investigations

- 3 Indian Pharmacopoeial Standards, BIS standards and ISO and other relevant standards 12 Hrs

- 4 Bioavailability and Bioequivalence data (BA &BE), BCS Classification of Drugs, Regulatory Requirements for Bioequivalence study 12 Hrs
Stability requirements: ICH and WHO

Guidelines for Drug testing in animals/Preclinical Studies

Animal testing: Rationale for conducting studies, CPCSEA Guidelines

Ethical guidelines for human participants

ICMR-DBT Guidelines for Stem Cell Research

- 5 Intellectual Property Rights: Patent, Trademark, Copyright, Industrial Designs and Geographical Indications, Indian Patent Scenario. IPR vs Regulatory Affairs 12 Hrs

REFERENCES

1. Manual of Patent Practice & Procedure, 3rd Edition, by The Patent Office of India
2. Patent Failure How Judges, Bureaucrats, and Lawyers put innovators at risk by James Bessen and Michael J. Meurer
3. Principles and Practice of Clinical Trial Medicine by Richard Chin and Bruce Y. Lee
4. Ethical Guidelines for Biomedical Research on Human Participants by Indian Council of Medical Research New delhi 2006.
5. CPCSEA Guidelines for Laboratory Animal Facility by Committee for the purpose of control and supervision on experiments on animals (CPCSEA)

6. ICH E6 Guideline — Good Clinical Practice| by ICH Harmonised Tripartite
7. Guidance for Industry on Submission of Clinical Trial Application for Evaluating Safety and Efficacy by CDSCO (Central Drug Standard Control Organisation)
8. Guidance for Industry on Requirement of Chemical & Pharmaceutical Information including Stability Study Data before approval of clinical trials / BE studies by CDSCO
9. Guidelines for Import and Manufacture of Medical Devices by CDSCO
10. Guidelines from official website of CDSCO

REGULATORY AFFAIRS PRACTICAL - I
(MRA 105P)

1. Case studies (4 Nos.) of each of Good Pharmaceutical Practices.
2. Documentation for in process and finished products Quality control tests for Solid, liquid, Semisolid and Sterile preparations.
3. Preparation of SOPs, Analytical reports (Stability and validation)
4. Protocol preparation for documentation of various types of records (BMR, MFR, DR)
5. Labeling comparison between brand & generics.
6. Preparation of clinical trial protocol for registering trial in India
7. Registration for conducting BA/ BE studies in India
8. Import of drugs for research and developmental activities
9. Preparation of regulatory dossier as per Indian CTD format and submission in SUGAM
10. Registering for different Intellectual Property Rights in India
11. GMP Audit Requirements as per CDSCO
12. Preparation and documentation for Indian Patent application.
13. Preparation of checklist for registration of IND as per ICH CTD format.
14. Preparation of checklist for registration of NDA as per ICH CTD format.
15. Preparation of checklist for registration of ANDA as per ICH CTD format.
16. Case studies on response with scientific rationale to USFDA Warning Letter
17. Preparation of submission checklist of IMPD for EU submission.
18. Comparison study of marketing authorization procedures in EU.
19. Comparative study of DMF system in US, EU and Japan
20. Preparation of regulatory submission using eCTD software
21. Preparation of Clinical Trial Application (CTA) for US submission
22. Preparation of Clinical Trial Application (CTA) for EU submission
23. Comparison of Clinical Trial Application requirements of US, EU and Japan of a dosage form.
24. Regulatory requirements checklist for conducting clinical trials in India.
25. Regulatory requirements checklist for conducting clinical trials in Europe.
26. Regulatory requirements checklist for conducting clinical trials in USA

SEMESTER II
REGULATORY ASPECTS OF DRUGS & COSMETICS
(MRA 201T)

Scope

This course is designed to impart the fundamental knowledge on the drug development process, regulatory requirements for approval of new drugs, drug products and cosmetics in regulated and semi-regulated countries. It prepares the students to learn in detail on the regulatory requirements, documentation requirements, and registration procedures for marketing the drug products and cosmetics in regulated and semi-regulated countries.

Objectives

Upon completion of the course, the student shall be able to know

- process of drug discovery and development and generic product development
- regulatory approval process and registration procedures for API and drug products in US, EU
- Cosmetics regulations in regulated and semi-regulated countries
- A comparative study of India with other global regulated markets

Theory

60 Hrs

1. USA & CANADA: Organization structure and functions of FDA. 12 Hrs
Federal register and Code of Federal Regulations (CFR), History and evolution of United States Federal, Food, Drug and Cosmetic Act (FFDCA), Hatch Waxman act and Orange book, Purple book, Drug Master Files (DMF) system in US, Regulatory Approval Process for Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Supplemental New Drug Application (SNDA); Regulatory requirements for Orphan drugs and Combination Products, Changes to an approved NDA / ANDA. Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in USA. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in USA and Canada.
2. European Union & Australia: Organization and structure of EMA & EDQM, General guidelines, Active Substance Master Files (ASMF) system in EU, Content and approval process of IMPD, Marketing Authorization procedures in EU (Centralized procedure,

Decentralized procedure, Mutual recognition procedure and National Procedure). Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in EU, Eudralex directives for human medicines, Variations & extensions, Compliance of European Pharmacopoeia (CEP)/ Certificate of Suitability (CoS), Marketing Authorization (MA) transfers, Qualified Person (QP) in EU. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in European Union & Australia.

- 3 Japan: Organization of the PMDA, Pharmaceutical Laws and regulations, types of registration applications, DMF system in Japan, drug regulatory approval process, Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in Japan, Post marketing surveillance in Japan. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in Japan 12 Hrs

- 4 Emerging Market: Introduction, Countries covered, Study of the world map, study of various committees across the globe (ASEAN, APEC, EAC, GCC, PANDRH, SADC) 12 Hrs
 WHO: WHO, GMP, Regulatory Requirements for registration of drugs and post approval requirements in WHO through prequalification programme, Certificate of Pharmaceutical Product (CoPP) - General and Country Specific (South Africa, Egypt, Algeria and Morocco, Nigeria, Kenya and Botswana)

- 5 Brazil, ASEAN, CIS and GCC Countries: 12 Hrs
 ASIAN Countries: Introduction to ACTD, Regulatory Requirements for registration of drugs and post approval requirements in China and South Korea & Association of Southeast Asian Nations (ASEAN) Region i.e. Vietnam, Malaysia, Philippines, Singapore and Thailand.
 CIS (Commonwealth Independent States): Regulatory pre-requisites related to Marketing authorization requirements for drugs and post approval requirements in CIS countries i.e. Russia, Kazakhstan and Ukraine
 GCC (Gulf Cooperation Council) for Arab states: Regulatory pre-requisites related to Marketing authorization requirements for drugs and post approval requirements in Saudi Arabia and UAE
 Legislation and regulations for import, manufacture, distribution and sale of cosmetics in Brazil, ASEAN, CIS and GCC Countries.

REFERENCES :

1. Generic Drug Product Development, Solid Oral Dosage forms, Leon Shargel and Isader Kaufer, Marcel Dekker series, Vol.143
2. The Pharmaceutical Regulatory Process, Edited by Ira R. Berry Marcel Dekker Series, Vol.144
3. The Pharmaceutical Regulatory Process, Second Edition Edited by Ira R. Berry and Robert P. Martin, Drugs and the Pharmaceutical Sciences, Vol.185 Informa Health care Publishers.
4. New Drug Approval Process: Accelerating Global Registrations By Richard A Guarino, MD, 5th edition, Drugs and the Pharmaceutical Sciences, Vol.190.
5. Guidebook for drug regulatory submissions / Sandy Weinberg. By John Wiley & Sons. Inc.
6. Drugs: From Discovery to Approval, Second Edition By Rick Ng
7. New Drug Development: A Regulatory Overview, Eighth Edition By Mark Mathieu
8. Pharmaceutical Risk Management By Jeffrey E. Fetterman, Wayne L. Pines and Gary H. Slatko
9. Preparation and Maintenance of the IND Application in eCTD Format By William K. Sietsema
10. Country Specific Guidelines from official websites.
11. http://www.who.int/medicines/areas/quality_safety/regulation_legislation/ListMRAWebsites.pdf
12. Roadmap to an ASEAN economic community Edited by Denis Hew. ISEAS Publications, Singapore 2005, ISBN981-230-347-2
13. ASEAN, Rodolfo C. Severino, ISEAS Publications, Singapore 2005, ISBN 978-981-230-750-7
14. Building a Future with Brics: The Next Decade for Offshoring, .Mark Kobayashi-Hillary, Springer
15. Outsourcing to India: The Offshore Advantage, Mark Kobayashi-Hillary, Springer Trade performance and Regional Integration of the CIS Countries, Lev Freinkman,
16. The world Bank, Washington, DC, ISBN: 0-8212-5896-0
17. Global Pharmaceutical Policy: Ensuring Medicines for Tomorrow's World ByFrederick M. Abbott, Graham Dukes, Maurice Nelson Graham Dukes 139
18. The Gulf Cooperation Council: A Rising Power and Lessons for ASEAN by Linda Low and Lorraine Carlos Salazar (Nov 22, 2010)
19. Doing Business in the Asean Countries, Balbir Bhasin, Business Expert Press ISBN:13:978-1-60649-108-9
20. Realizing the ASEAN Economic Community: A Comprehensive Assessment, Michael G Plummer (Editor), Chia Siow Yue (Editor), Instute of South east asian studies, Singapore

**REGULATORY ASPECTS OF HERBAL AND BIOLOGICALS
(MRA 202T)**

Scope

This course is designed to impart fundamental knowledge on Regulatory Requirements, Licensing and Registration, Regulation on Labelling of Biologics in India, USA and Europe
It prepares the students to learn in detail on Regulatory Requirements for biologics, Vaccines and Blood Products

Objectives

Upon the completion of the course the student shall be able to :

- Know the regulatory Requirements for Biologics and Vaccines
- Understand the regulation for newly developed biologics and biosimilars
- Know the pre-clinical and clinical development considerations of biologics
- Understand the Regulatory Requirements of Blood and/or Its Components Including Blood Products and label requirements

Theory

60 Hrs

1. India : Introduction, Applicable Regulations and Guidelines , 12 Hrs
Principles for Development of Similar Biologics, Data Requirements for Preclinical Studies, Data Requirements for Clinical Trial Application, Data Requirements for Market Authorization Application, Post-Market Data for Similar Biologics, Pharmacovigilance. GMP and GDP.
2. USA: Introduction to Biologics; biologics, biological and biosimilars, different biological products, difference between generic drug and biosimilars, laws, regulations and guidance on biologics/ biosimilars, development and approval of biologics and biosimilars (IND, PMA, BLA, NDA, 510(k), pre-clinical and clinical development considerations, advertising, labelling and packing of biologics 12 Hrs
3. European Union: Introduction to Biologics; directives, scientific guidelines and guidance related to biologics in EU, comparability/ biosimilarity assessment, Plasma master file, TSE/ BSE evaluation, development and regulatory approval of biologics (Investigational medicinal products and biosimilars), pre-clinical 12 Hrs

and clinical development considerations; stability, safety, advertising, labelling and packing of biologics in EU

- | | | |
|---|--|-----------|
| 4 | Vaccine regulations in India, US and European Union: Clinical evaluation, Marketing authorisation, Registration or licensing, Quality assessment, Pharmacovigilance, Additional requirements Blood and Blood Products Regulations in India, US and European Union: Regulatory Requirements of Blood and/or Its Components Including Blood Products, Label Requirements, ISBT (International Society of Blood Transfusion) and IHN (International Haemovigilance Network) | 12
Hrs |
| 5 | Herbal Products: Quality, safety and legislation for herbal products in India, USA and European Union. | 12
Hrs |

REFERENCES

1. FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics, Douglas J. Pisano , David S. Mantus ; Informa ,2008
2. Biological Drug Products: Development and Strategies; Wei Wang , Manmohan Singh ; wiley ,2013
3. Development of Vaccines: From Discovery to Clinical Testing; Manmohan Singh , Indresh K. Srivastava ;Wiley, 2011
4. www.who.int/biologicals/en
5. www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/
6. www.ihn-org.com
7. www.isbtweb.org
8. Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India
9. www.cdsc.nic.in
10. www.ema.europa.eu > scientific guidelines > Biologics
11. www.fda.gov/biologicsbloodvaccines/guidancecompliance Regulatory Information (Biologics)

**REGULATORY ASPECTS OF MEDICAL DEVICES
(MRA 203T)**

Scope

This course is designed to impart the fundamental knowledge on the medical devices and in vitro diagnostics, basis of classification and product life cycle of medical devices, regulatory requirements for approval of medical devices in regulated countries like US, EU and Asian countries along with WHO regulations. It prepares the students to learn in detail on the harmonization initiatives, quality and ethical considerations, regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.

Objectives

Upon completion of the course, the student shall be able to know

- basics of medical devices and IVDs, process of development, ethical and quality considerations
- harmonization initiatives for approval and marketing of medical devices and IVDs
- regulatory approval process for medical devices and IVDs in India, US, Canada, EU, Japan and ASEAN
- clinical evaluation and investigation of medical devices and IVDs

Theory

60 Hrs

1. Medical Devices: Introduction, Definition, Risk based classification and Essential Principles of Medical Devices and IVDs. Differentiating medical devices IVDs and Combination Products from that of pharmaceuticals, History of Medical Device Regulation, Product Lifecycle of Medical Devices and Classification of Medical Devices. 12 Hrs
IMDRF/GHTF: Introduction, Organizational Structure, Purpose and Functions, Regulatory Guidelines, Working Groups, Summary Technical Document (STED), Global Medical Device Nomenclature (GMDN).
2. Ethics: Clinical Investigation of Medical Devices, Clinical Investigation Plan for Medical Devices, Good Clinical Practice for Clinical Investigation of medical devices (ISO 14155:2011) 12 Hrs
Quality: Quality System Regulations of Medical Devices: ISO 13485, Quality Risk Management of Medical Devices: ISO 14971, Validation and Verification of Medical device, Adverse Event Reporting of Medical device

- 3 USA: Introduction, Classification, Regulatory approval process for Medical Devices (510k) Premarket Notification, Pre-Market Approval (PMA), Investigational Device Exemption (IDE) and In vitro Diagnostics, Quality System Requirements 21 CFR Part 820, Labeling requirements 21 CFR Part 801, Post marketing surveillance of MD and Unique Device Identification (UDI). Basics of In vitro diagnostics, classification and approval process. 12 Hrs
- 4 European Union: Introduction, Classification, Regulatory approval process for Medical Devices (Medical Device Directive, Active Implantable Medical Device Directive) and In vitro Diagnostics (In Vitro Diagnostics Directive), CE certification process. Basics of In vitro diagnostics, classification and approval process. 12 Hrs
- 5 ASEAN, China & Japan: Medical Devices and IVDs, Regulatory registration procedures, Quality System requirements and clinical evaluation and investigation. IMDRF study groups and guidance documents. 12 Hrs

REFERENCES

1. FDA regulatory affairs: a guide for prescription drugs, medical devices, and biologics by Douglas J. Pisano, David Mantus.
2. Medical Device Development: A Regulatory Overview by Jonathan S. Kahan
3. Medical Product Regulatory Affairs: Pharmaceuticals, Diagnostics, Medical Devices by John J. Tobin and Gary Walsh
4. Compliance Handbook for Pharmaceuticals, Medical Devices and Biologics by Carmen Medina
5. Country Specific Guidelines from official websites.

REGULATORY ASPECTS OF FOOD & NUTRACEUTICALS
(MRA 204T)

Scope

This course is designed to impart the fundamental knowledge on Regulatory Requirements, Registration and Labeling Regulations of Nutraceuticals in India, USA and Europe. It prepares the students to learn in detail on Regulatory Aspects for nutraceuticals and food supplements.

Objectives

Upon completion of the course, the student shall be able to

- Know the regulatory Requirements for nutraceuticals
- Understand the regulation for registration and labeling of nutraceuticals and food supplements in India, USA and Europe.

Theory

60 Hrs

1. Nutraceuticals: Introduction, History of Food and Nutraceutical Regulations, Meaning of Nutraceuticals, Dietary Supplements, Functional Foods, Medical Foods, Scope and Opportunities in Nutraceutical Market. 12 Hrs
2. Global Aspects: WHO guidelines on nutrition. NSF International: Its Role in the Dietary Supplements and Nutraceuticals Industries, NSF Certification, NSF Standards for Food And Dietary Supplements. Good Manufacturing Practices for Nutraceuticals. 12 Hrs
3. India : Food Safety and Standards Act, Food Safety and Standards Authority of India: Organization and Functions, Regulations for import, manufacture and sale of nutraceutical products in India, Recommended Dietary Allowances (RDA) in India. 12 Hrs
4. USA: US FDA Food Safety Modernization Act, Dietary Supplement Health and Education Act. U.S. regulations for manufacture and sale of nutraceuticals and dietary supplements, Labelling Requirements and Label Claims for Dietary Supplements, Recommended Dietary Allowances (RDA) in the U.S 12 Hrs

- 5 European Union: European Food Safety Authority (EFSA): 12
Organization and Functions. EU Directives and regulations for Hrs
manufacture and sale of nutraceuticals and dietary supplements.
Nutrition labelling. European Regulation on Novel Foods and
Novel Food Ingredients. Recommended Dietary Allowances
(RDA) in Europe.

REFERENCES

1. Regulation of Functional Foods and Nutraceuticals: A Global Perspective
by Clare M. Hasler (Wiley Online Library)
2. Nutraceutical and Functional Food Regulations in the United States and
Around the World by Debasis Bagchi (Academic Press, Elsevier)
3. <http://www.who.int/publications/guidelines/nutrition/en/>
4. [http://www.europarl.europa.eu/RegData/etudes/STUD/2015/536324/IPOL_](http://www.europarl.europa.eu/RegData/etudes/STUD/2015/536324/IPOL_STU(2015)536324_EN.pdf)
[STU\(2015\)536324_EN.pdf](http://www.europarl.europa.eu/RegData/etudes/STUD/2015/536324/IPOL_STU(2015)536324_EN.pdf)
5. Handbook of Nutraceuticals by Yashwant Pathak (CRC Press)
6. Food Regulation: Law, Science, Policy and Practice by Neal D. Fortin
(Wiley)
7. Country Specific Guidelines from official websites.

REGULATORY AFFAIRS PRACTICAL - II
(MRA 205P)

1. Case studies on
2. Change Management/ Change control. Deviations
3. Corrective & Preventive Actions (CAPA)
4. Documentation of raw materials analysis as per official monographs
5. Preparation of audit checklist for various agencies
6. Preparation of submission to FDA using eCTD software
7. Preparation of submission to EMA using eCTD software
8. Preparation of submission to MHRA using eCTD software
9. Preparation of Biologics License Applications (BLA)
10. Preparation of documents required for Vaccine Product Approval
11. Comparison of clinical trial application requirements of US, EU and India of Biologics
12. Preparation of Checklist for Registration of Blood and Blood Products
13. Registration requirement comparison study in 5 emerging markets (WHO) and preparing check list for market authorization
14. Registration requirement comparison study in emerging markets (BRICS) and preparing check list for market authorization
15. Registration requirement comparison study in emerging markets (China and South Korea) and preparing check list for market authorization
16. Registration requirement comparison study in emerging markets (ASEAN) and preparing check list for market authorization
17. Registration requirement comparison study in emerging markets (GCC) and preparing check list for market authorization
18. Checklists for 510k and PMA for US market
19. Checklist for CE marking for various classes of devices for EU
20. STED Application for Class III Devices
21. Audit Checklist for Medical Device Facility
22. Clinical Investigation Plan for Medical Devices

PHARMACOLOGY (MPL)

MODERN PHARMACEUTICAL ANALYTICAL TECHNIQUES (MPL 101T)

Scope

This subject deals with various advanced analytical instrumental techniques for identification, characterization and quantification of drugs. Instruments dealt are NMR, Mass spectrometer, IR, HPLC, GC etc.

Objectives

After completion of course student is able to know about,

- Chemicals and Excipients
- The analysis of various drugs in single and combination dosage forms
- Theoretical and practical skills of the instruments

THEORY

- | | |
|--|--------|
| | 60 Hrs |
| 1. UV-Visible spectroscopy: Introduction, Theory, Laws, Instrumentation associated with UV-Visible spectroscopy, Choice of solvents and solvent effect and Applications of UV-Visible spectroscopy, Difference/ Derivative spectroscopy. IR spectroscopy: Theory, Modes of Molecular vibrations, Sample handling, Instrumentation of Dispersive and Fourier - Transform IR Spectrometer, Factors affecting vibrational frequencies and Applications of IR spectroscopy, Data Interpretation. Spectrofluorimetry: Theory of Fluorescence, Factors affecting fluorescence (Characteristics of drugs that can be analysed by fluorimetry), Quenchers, Instrumentation and Applications of fluorescence spectrophotometer. Flame emission spectroscopy and Atomic absorption spectroscopy: Principle, Instrumentation, Interferences and Applications. | 10 Hrs |
| 2. NMR spectroscopy: Quantum numbers and their role in NMR, Principle, Instrumentation, Solvent requirement in NMR, Relaxation process, NMR signals in various compounds, Chemical shift, Factors influencing chemical shift, Spin-Spin coupling, Coupling constant, Nuclear magnetic double resonance, Brief outline of principles of FT-NMR and ¹³ C NMR. Applications of NMR spectroscopy. | 10 Hrs |

- | | | |
|---|---|-----------|
| 3 | Mass Spectroscopy: Principle, Theory, Instrumentation of Mass Spectroscopy, Different types of ionization like electron impact, chemical, field, FAB and MALDI, APCI, ESI, APPI Analyzers of Quadrupole and Time of Flight, Mass fragmentation and its rules, Meta stable ions, Isotopic peaks and Applications of Mass spectroscopy. | 10
Hrs |
| 4 | Chromatography: Principle, apparatus, instrumentation, chromatographic parameters, factors affecting resolution, isolation of drug from excipients, data interpretation and applications of the following:
j) Thin Layer chromatography
k) High Performance Thin Layer Chromatography
l) Ion exchange chromatography
m) Column chromatography
n) Gas chromatography
o) High Performance Liquid chromatography
p) Ultra High Performance Liquid chromatography
q) Affinity chromatography
r) Gel Chromatography | 10
Hrs |
| 5 | Electrophoresis: Principle, Instrumentation, Working conditions, factors affecting separation and applications of the following:
a) Paper electrophoresis b) Gel electrophoresis c) Capillary electrophoresis d) Zone electrophoresis e) Moving boundary electrophoresis f) Iso electric focusing
X ray Crystallography: Production of X rays, Different X ray methods, Bragg's law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of X-ray diffraction. | 10
Hrs |
| 6 | Potentiometry: Principle, working, Ion selective Electrodes and Application of potentiometry.
Thermal Techniques: Principle, thermal transitions and Instrumentation (Heat flux and power-compensation and designs), Modulated DSC, Hyper DSC, experimental parameters (sample preparation, experimental conditions, calibration, heating and cooling rates, resolution, source of errors) and their influence, advantage and disadvantages, pharmaceutical applications. Differential Thermal Analysis (DTA): Principle, instrumentation and advantage and disadvantages, pharmaceutical applications, derivative differential thermal analysis (DDTA). TGA: Principle, instrumentation, factors affecting results, advantage and disadvantages, pharmaceutical applications. | 10
Hrs |

REFERENCES

1. Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley & Sons, 2004.
2. Principles of Instrumental Analysis - Douglas A Skoog, F. James Holler, Timothy A. Nieman, 5th edition, Eastern press, Bangalore, 1998.
3. Instrumental methods of analysis - Willards, 7th edition, CBS publishers.
4. Practical Pharmaceutical Chemistry - Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.
5. Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.
6. Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.
7. Pharmaceutical Analysis - Modern Methods - Part B - J W Munson, Vol 11, Marcel. Dekker Series
8. Spectroscopy of Organic Compounds, 2nd edn., P.S/Kalsi, Wiley estern Ltd., Delhi.
9. Textbook of Pharmaceutical Analysis, KA.Connors, 3rd Edition, John Wiley & Sons, 1982.

ADVANCED PHARMACOLOGY - I
(MPL 102T)

Scope

The subject is designed to strengthen the basic knowledge in the field of pharmacology and to impart recent advances in the drugs used for the treatment of various diseases. In addition, this subject helps the students to understand the concepts of drug action and mechanisms involved

Objectives

Upon completion of the course the student shall be able to :

- Discuss the pathophysiology and pharmacotherapy of certain diseases
- Explain the mechanism of drug actions at cellular and molecular level
- Understand the adverse effects, contraindications and clinical uses of drugs used in treatment of diseases

THEORY

60 Hrs

- | | |
|--|---------------------|
| 1. General | Pharmacology 12 Hrs |
| a. Pharmacokinetics: The dynamics of drug absorption, distribution, biotransformation and elimination. Concepts of linear and non-linear compartment models. Significance of Protein binding. | |
| b. Pharmacodynamics: Mechanism of drug action and the relationship between drug concentration and effect. Receptors, structural and functional families of receptors, quantitation of drug receptors interaction and elicited effects. | |
| 2 Neurotransmission | 12 Hrs |
| a. General aspects and steps involved in neurotransmission. | |
| b. Neurohumoral transmission in autonomic nervous system (Detailed study about neurotransmitters- Adrenaline and Acetyl choline). | |
| c. Neurohumoral transmission in central nervous system (Detailed study about neurotransmitters- histamine, serotonin, dopamine, GABA, glutamate and glycine). | |
| d. Non adrenergic non cholinergic transmission (NANC). Co-transmission | |

Systemic Pharmacology

A detailed study on pathophysiology of diseases, mechanism of action, pharmacology and toxicology of existing as well as novel drugs used in the following systems

Autonomic Pharmacology

Parasympathomimetics and lytics, sympathomimetics and lytics, agents affecting neuromuscular junction

- | | | |
|---|---|-----------|
| 3 | Central nervous system Pharmacology
General and local anesthetics
Sedatives and hypnotics, drugs used to treat anxiety.
Depression, psychosis, mania, epilepsy, neurodegenerative diseases.
Narcotic and non-narcotic analgesics. | 12
Hrs |
| 4 | Cardiovascular Pharmacology
Diuretics, antihypertensives, antiischemics, anti-arrhythmics, drugs for heart failure and hyperlipidemia.
Hematinics, coagulants, anticoagulants, fibrinolytics and anti-platelet drugs | 12
Hrs |
| 5 | Autocoid Pharmacology
The physiological and pathological role of Histamine, Serotonin, Kinins Prostaglandins Opioid autocoids.
Pharmacology of antihistamines, 5HT antagonists. | 12
Hrs |

REFEERENCES

1. The Pharmacological Basis of Therapeutics, Goodman and Gillman's
2. Principles of Pharmacology. The Pathophysiologic basis of drug Therapy by David E Golan, Armen H, Tashjian Jr, Ehrin J, Armstrong; April W, Armstrong, Wolters, Kluwer-Lippincott Williams & Wilkins Publishers.
3. Basic and Clinical Pharmacology by B.G Katzung
4. Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott.
5. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.
6. Graham Smith. Oxford textbook of Clinical Pharmacology.
7. Avery Drug Treatment
8. Dipiro Pharmacology, Pathophysiological approach.
9. Green Pathophysiology for Pharmacists.

10. Robbins & Cortan Pathologic Basis of Disease, 9th Ed. (Robbins Pathology)
11. A Complete Textbook of Medical Pharmacology by Dr. S.K. Srivastava published by APC Avichal Publishing Company
12. KD.Tripathi. Essentials of Medical Pharmacology.
13. Modern Pharmacology with Clinical Applications, Craig Charles R. & Stitzel Robert E., Lippincott Publishers.
14. Clinical Pharmacokinetics & Pharmacodynamics : Concepts and Applications - Malcolm Rowland and Thomas N.Tozer, Wolters Kluwer, Lippincott Williams & Wilkins Publishers.
15. Applied biopharmaceutics and Pharmacokinetics, Pharmacodynamics and Drug metabolism for industrial scientists.
16. Modern Pharmacology, Craig CR. & Stitzel RE, Little Brown & Company.

PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING
METHODS - I
(MPL 103T)

Scope

This subject is designed to impart the knowledge on preclinical evaluation of drugs and recent experimental techniques in the drug discovery and development. The subject content helps the student to understand the maintenance of laboratory animals as per the guidelines, basic knowledge of various in-vitro and in-vivo preclinical evaluation processes

Objectives

Upon completion of the course the student shall be able to,

- Appraise the regulations and ethical requirement for the usage of experimental animals.
- Describe the various animals used in the drug discovery process and good laboratory practices in maintenance and handling of experimental animals
- Describe the various newer screening methods involved in the drug discovery process
- Appreciate and correlate the preclinical data to humans

THEORY	60 Hrs
1. Laboratory Animals	12
Common laboratory animals: Description, handling and applications of different species and strains of animals.	Hrs
Transgenic animals: Production, maintenance and applications	
Anaesthesia and euthanasia of experimental animals.	
Maintenance and breeding of laboratory animals.	
CPCSEA guidelines to conduct experiments on animals	
Good laboratory practice.	
Bioassay-Principle, scope and limitations and methods	
2. Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models.	12 Hrs
General principles of preclinical screening. CNS Pharmacology: behavioral and muscle co ordination, CNS stimulants and	

depressants, anxiolytics, anti-psychotics, anti epileptics and
nootropics. Drugs for neurodegenerative diseases like
Parkinsonism, Alzheimers and multiple sclerosis. Drugs acting on
Autonomic Nervous System.

- 3 Preclinical screening of new substances for the 12
pharmacological activity using in vivo, in vitro, and other Hrs
possible animal alternative models.

Respiratory Pharmacology: anti-asthmatics, drugs for COPD and
anti allergics. Reproductive Pharmacology: Aphrodisiacs and
antifertility agents Analgesics, antiinflammatory and antipyretic
agents. Gastrointestinal drugs: anti ulcer, anti -emetic, anti-
diarrheal and laxatives.

- 4 Preclinical screening of new substances for the 12
pharmacological activity using in vivo, in vitro, and other Hrs
possible animal alternative models.

Cardiovascular Pharmacology: antihypertensives, antiarrhythmics,
antianginal, antiatherosclerotic agents and diuretics. Drugs for
metabolic disorders like anti-diabetic, antidyslipidemic agents.
Anti cancer agents. Hepatoprotective screening methods.

- 5 Preclinical screening of new substances for the 12
pharmacological activity using in vivo, in vitro, and other Hrs
possible animal alternative models.

Immunomodulators, Immunosuppressants and immunostimulants

General principles of immunoassay: theoretical basis and
optimization of immunoassay, heterogeneous and homogenous
immunoassay systems. Immunoassay methods evaluation;
protocol outline, objectives and preparation. Immunoassay for
digoxin and insulin

Limitations of animal experimentation and alternate animal
experiments.

Extrapolation of in vitro data to preclinical and preclinical to
humans

REFERENCES

1. Biological standardization by J.H. Burn D.J. Finney and I.G. Goodwin
2. Screening methods in Pharmacology by Robert Turner. A
3. Evaluation of drugs activities by Laurence and Bachrach
4. Methods in Pharmacology by Arnold Schwartz.
5. Fundamentals of experimental Pharmacology by M.N.Ghosh
6. Pharmacological experiment on intact preparations by Churchill Livingstone
7. Drug discovery and Evaluation by Vogel H.G.
8. Experimental Pharmacology by R.K.Goyal.
9. Preclinical evaluation of new drugs by S.K. Guta
10. Handbook of Experimental Pharmacology, SK.Kulkarni
11. Practical Pharmacology and Clinical Pharmacy, SK.Kulkarni, 3rd Edition.
12. David R.Gross. Animal Models in Cardiovascular Research, 2nd Edition, Kluwer Academic Publishers, London, UK.
13. Screening Methods in Pharmacology, Robert A.Turner.
14. Rodents for Pharmacological Experiments, Dr.Tapan Kumar chatterjee.
15. Practical Manual of Experimental and Clinical Pharmacology by Bikash Medhi (Author), Ajay Prakash (Author)

CELLULAR AND MOLECULAR PHARMACOLOGY
(MPL 104T)

Scope:

The subject imparts a fundamental knowledge on the structure and functions of cellular components and help to understand the interaction of these components with drugs. This information will further help the student to apply the knowledge in drug discovery process.

Objectives:

Upon completion of the course, the student shall be able to,

- Explain the receptor signal transduction processes.
- Explain the molecular pathways affected by drugs.
- Appreciate the applicability of molecular pharmacology and biomarkers in drug discovery process.
- Demonstrate molecular biology techniques as applicable for pharmacology

THEORY	60 Hrs
1. Cell biology	12
Structure and functions of cell and its organelles	Hrs
Genome organization. Gene expression and its regulation, importance of siRNA and micro RNA, gene mapping and gene sequencing	
Cell cycles and its regulation.	
Cell death- events, regulators, intrinsic and extrinsic pathways of apoptosis.	
Necrosis and autophagy.	
2 Cell signaling	12
Intercellular and intracellular signaling pathways.	Hrs
Classification of receptor family and molecular structure ligand gated ion channels; G-protein coupled receptors, tyrosine kinase receptors and nuclear receptors.	
Secondary messengers: cyclic AMP, cyclic GMP, calcium ion, inositol 1,4,5-trisphosphate, (IP3), NO, and diacylglycerol.	
Detailed study of following intracellular signaling pathways: cyclic AMP signaling pathway, mitogen-activated protein kinase (MAPK) signaling, Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway.	

- 3 Principles and applications of genomic and proteomic tools 12 Hrs
 DNA electrophoresis, PCR (reverse transcription and real time),
 Gene sequencing, micro array technique, SDS page, ELISA and
 western blotting,
 Recombinant DNA technology and gene therapy
 Basic principles of recombinant DNA technology-Restriction
 enzymes, various types of vectors. Applications of recombinant
 DNA technology.
 Gene therapy- Various types of gene transfer techniques, clinical
 applications and recent advances in gene therapy.
- 4 Pharmacogenomics 12 Hrs
 Gene mapping and cloning of disease gene.
 Genetic variation and its role in health/ pharmacology
 Polymorphisms affecting drug metabolism
 Genetic variation in drug transporters
 Genetic variation in G protein coupled receptors
 Applications of proteomics science: Genomics, proteomics,
 metabolomics, functionomics, nutrigenomics
 Immunotherapeutics
 Types of immunotherapeutics, humanisation antibody therapy,
 Immunotherapeutics in clinical practice
- 5 a. Cell culture techniques 12 Hrs
 Basic equipments used in cell culture lab. Cell culture media,
 various types of cell culture, general procedure for cell cultures;
 isolation of cells, subculture, cryopreservation, characterization of
 cells and their application.
 Principles and applications of cell viability assays, glucose uptake
 assay, Calcium influx assays
 Principles and applications of flow cytometry
 b. Biosimilars

REFERENCES:

1. The Cell, A Molecular Approach. Geoffrey M Cooper.
2. Pharmacogenomics: The Search for Individualized Therapies. Edited by J. Licinio and M-L. Wong
3. Handbook of Cell Signaling (Second Edition) Edited by Ralph A. et.al
4. Molecular Pharmacology: From DNA to Drug Discovery. John Dickenson et.al
5. Basic Cell Culture protocols by Cheril D.Helgason and Cindy L.Miller
6. Basic Cell Culture (Practical Approach) by J. M. Davis (Editor)
7. Animal Cell Culture: A Practical Approach by John R. Masters (Editor)
8. Current porotocols in molecular biology vol I to VI edited by Frederick M.Ausuvel et la.

PHARMACOLOGICAL PRACTICAL - I
(MPL 105P)

1. Analysis of pharmacopoeial compounds and their formulations by UV Vis spectrophotometer
2. Simultaneous estimation of multi component containing formulations by UV spectrophotometry
3. Experiments based on HPLC
4. Experiments based on Gas Chromatography
5. Estimation of riboflavin/quinine sulphate by fluorimetry
6. Estimation of sodium/potassium by flame photometry

Handling of laboratory animals.

1. Various routes of drug administration.
2. Techniques of blood sampling, anesthesia and euthanasia of experimental animals.
3. Functional observation battery tests (modified Irwin test)
4. Evaluation of CNS stimulant, depressant, anxiogenics and anxiolytic, anticonvulsant activity.
5. Evaluation of analgesic, anti-inflammatory, local anesthetic, mydriatic and miotic activity.
6. Evaluation of diuretic activity.
7. Evaluation of antiulcer activity by pylorus ligation method.
8. Oral glucose tolerance test.
9. Isolation and identification of DNA from various sources (Bacteria, Cauliflower, onion, Goat liver).
10. Isolation of RNA from yeast
11. Estimation of proteins by Bradford/Lowry's in biological samples.
12. Estimation of RNA/DNA by UV Spectroscopy
13. Gene amplification by PCR.
14. Protein quantification Western Blotting.
15. Enzyme based in-vitro assays (MPO, AChEs, α amylase, α glucosidase).
16. Cell viability assays (MTT/Trypan blue/SRB).
17. DNA fragmentation assay by agarose gel electrophoresis.
18. DNA damage study by Comet assay.
19. Apoptosis determination by fluorescent imaging studies.
20. Pharmacokinetic studies and data analysis of drugs given by different routes of administration using softwares
21. Enzyme inhibition and induction activity
22. Extraction of drug from various biological samples and estimation of drugs in biological fluids using different analytical techniques (UV)
23. Extraction of drug from various biological samples and estimation of drugs in biological fluids using different analytical techniques (HPLC)

REFERENCES

1. CPCSEA, OECD, ICH, USFDA, Schedule Y, EPA guidelines,
2. Fundamentals of experimental Pharmacology by M.N.Ghosh
3. Handbook of Experimental Pharmacology by S.K. Kulkarni.
4. Drug discovery and Evaluation by Vogel H.G.
5. Spectrometric Identification of Organic compounds - Robert M Silverstein,
6. Principles of Instrumental Analysis - Douglas A Skoog, F. James Holler, Timothy A. Nieman,
7. Vogel's Text book of quantitative chemical analysis - Jeffery, Basset, Mendham, Denney,
8. Basic Cell Culture protocols by Cheril D. Helgason and Cindy L.Mille
9. Basic Cell Culture (Practical Approach) by J. M. Davis (Editor)
10. Animal Cell Culture: A Practical Approach by John R. Masters (Editor)
11. Practical Manual of Experimental and Clinical Pharmacology by Bikash Medhi(Author), Ajay Prakash (Author) Jaypee brothers' medical publishers Pvt. Ltd

ADVANCED PHARMACOLOGY - II
(MPL 201T)

Scope

The subject is designed to strengthen the basic knowledge in the field of pharmacology and to impart recent advances in the drugs used for the treatment of various diseases. In addition, the subject helps the student to understand the concepts of drug action and mechanism involved

Objectives

Upon completion of the course the student shall be able to:

- Explain the mechanism of drug actions at cellular and molecular level
- Discuss the Pathophysiology and pharmacotherapy of certain diseases
- Understand the adverse effects, contraindications and clinical uses of drugs used in treatment of diseases

THEORY	60 Hrs
1. Endocrine Pharmacology Molecular and cellular mechanism of action of hormones such as growth hormone, prolactin, thyroid, insulin and sex hormones Anti-thyroid drugs, Oral hypoglycemic agents, Oral contraceptives, Corticosteroids. Drugs affecting calcium regulation	12 Hrs
2. Chemotherapy Cellular and molecular mechanism of actions and resistance of antimicrobial agents such as β -lactams, aminoglycosides, quinolones, Macrolide antibiotics. Antifungal, antiviral, and anti-TB drugs.	12 Hrs
3. Chemotherapy Drugs used in Protozoal Infections Drugs used in the treatment of Helminthiasis Chemotherapy of cancer Immunopharmacology Cellular and biochemical mediators of inflammation and immune response. Allergic or hypersensitivity reactions. Pharmacotherapy of asthma and COPD. Immunosuppressants and Immunostimulants	12 Hrs

- | | | |
|---|---|-----------|
| 4 | <p>GIT Pharmacology
 Antiulcer drugs, Prokinetics, antiemetics, anti-diarrheals and drugs for constipation and irritable bowel syndrome.
 Chronopharmacology
 Biological and circadian rhythms, applications of chronotherapy in various diseases like cardiovascular disease, diabetes, asthma and peptic ulcer</p> | 12
Hrs |
| 5 | <p>Free radicals Pharmacology
 Generation of free radicals, role of free radicals in etiopathology of various diseases such as diabetes, neurodegenerative diseases and cancer.
 Protective activity of certain important antioxidant
 Recent Advances in Treatment:
 Alzheimer's disease, Parkinson's disease, Cancer, Diabetes mellitus</p> | 12
Hrs |

REFERENCES

1. The Pharmacological basis of therapeutics- Goodman and Gill man's
2. Principles of Pharmacology. The Pathophysiologic basis of drug therapy by David E Golan et al.
3. Basic and Clinical Pharmacology by B.G -Katzung
4. Pharmacology by H.P. Rang and M.M. Dale.
5. Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott.
6. Text book of Therapeutics, drug and disease management by E T. Herfindal and Gourley.
7. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.
8. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists
9. Robbins & Cortan Pathologic Basis of Disease, 9th Ed. (Robbins Pathology)
10. A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company.
11. KD.Tripathi. Essentials of Medical Pharmacology
12. Principles of Pharmacology. The Pathophysiologic basis of drug Therapy by David E Golan, Armen H, Tashjian Jr, Ehrin J, Armstrong, April W, Armstrong, Wolters, Kluwer-Lippincott Williams & Wilkins Publishers

PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING
METHODS-II
(MPL 202T)

Scope:

This subject imparts knowledge on the preclinical safety and toxicological evaluation of drug & new chemical entity. This knowledge will make the student competent in regulatory toxicological evaluation.

Objectives:

Upon completion of the course, the student shall be able to,

- Explain the various types of toxicity studies.
- Appreciate the importance of ethical and regulatory requirements for toxicity studies.
- Demonstrate the practical skills required to conduct the preclinical toxicity studies.

THEORY	60 Hrs
1. Basic definition and types of toxicology (general, mechanistic, regulatory and descriptive) Regulatory guidelines for conducting toxicity studies OECD, ICH, EPA and Schedule Y OECD principles of Good laboratory practice (GLP) History, concept and its importance in drug development	12 Hrs
2. Acute, sub-acute and chronic- oral, dermal and inhalational studies as per OECD guidelines. Acute eye irritation, skin sensitization, dermal irritation & dermal toxicity studies. Test item characterization- importance and methods in regulatory toxicology studies	12 Hrs
3. Reproductive toxicology studies, Male reproductive toxicity studies, female reproductive studies (segment I and segment III), teratogenicity studies (segment II) Genotoxicity studies (Ames Test, in vitro and in vivo Micronucleus and Chromosomal aberrations studies) In vivo carcinogenicity studies	12 Hrs
4. IND enabling studies (IND studies)- Definition of IND, importance of IND, industry perspective, list of studies needed for IND submission.	12 Hrs

Safety pharmacology studies- origin, concepts and importance of safety pharmacology.

Tier1- CVS, CNS and respiratory safety pharmacology, HERG assay. Tier2- GI, renal and other studies

- 5 Toxicokinetics- Toxicokinetic evaluation in preclinical studies, 12 saturation kinetics Importance and applications of toxicokinetic Hrs studies.
Alternative methods to animal toxicity testing.

REFERENCES

1. Hand book on GLP, Quality practices for regulated non-clinical research and development (<http://www.who.int/tdr/publications/documents/glp-handbook.pdf>).
2. Schedule Y Guideline: drugs and cosmetics (second amendment) rules, 2005, ministry of health and family welfare (department of health) New Delhi
3. Drugs from discovery to approval by Rick NG.
4. Animal Models in Toxicology, 3rd Edition, Lower and Bryan
5. OECD test guidelines.
6. Principles of toxicology by Karen E. Stine, Thomas M. Brown.
7. Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (<http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073246.pdf>)

PRINCIPLES OF DRUG DISCOVERY
(MPL 203T)

Scope:

The subject imparts basic knowledge of drug discovery process. This information will make the student competent in drug discovery process

Objectives:

Upon completion of the course, the student shall be able to,

- Explain the various stages of drug discovery.
- Appreciate the importance of the role of genomics, proteomics and bioinformatics in drug discovery
- Explain various targets for drug discovery.
- Explain various lead seeking method and lead optimization
- Appreciate the importance of the role of computer aided drug design in drug discovery

THEORY	60 Hrs
1. An overview of modern drug discovery process: Target identification, target validation, lead identification and lead Optimization. Economics of drug discovery. Target Discovery and validation-Role of Genomics, Proteomics and Bioinformatics. Role of Nucleic acid microarrays, Protein microarrays, Antisense technologies, siRNAs, antisense oligonucleotides, Zinc finger proteins. Role of transgenic animals in target validation.	12 Hrs
2. Lead Identification- combinatorial chemistry & high throughput screening, in silico lead discovery techniques, Assay development for hit identification. Protein structure Levels of protein structure, Domains, motifs, and folds in protein structure. Computational prediction of protein structure: Threading and homology modeling methods. Application of NMR and X-ray crystallography in protein structure prediction	12 Hrs
3. Rational Drug Design Traditional vs rational drug design, Methods followed in traditional drug design, High throughput screening, Concepts of Rational Drug Design, Rational Drug Design Methods: Structure and Pharmacophore based approaches	12 Hrs

Virtual Screening techniques: Drug likeness screening, Concept of pharmacophore mapping and pharmacophore based Screening,

- 4 Molecular docking: Rigid docking, flexible docking, manual docking; Docking based screening. De novo drug design. 12 Hrs
Quantitative analysis of Structure Activity Relationship
History and development of QSAR, SAR versus QSAR, Physicochemical parameters, Hansch analysis, Fee Wilson analysis and relationship between them.
- 5 QSAR Statistical methods - regression analysis, partial least square analysis (PLS) and other multivariate statistical methods. 12 Hrs
3D-QSAR approaches like COMFA and COMSIA
Prodrug design-Basic concept, Prodrugs to improve patient acceptability, Drug solubility, Drug absorption and distribution, site specific drug delivery and sustained drug action. Rationale of prodrug design and practical consideration of prodrug design

REFERENCES

1. MouldySioud. Target Discovery and Validation Reviews and Protocols: Volume 2 Emerging Molecular Targets and Treatment Options. 2007 Humana Press Inc.
2. Darryl León. Scott Markelln. Silico Technologies in Drug Target Identification and Validation. 2006 by Taylor and Francis Group, LLC.
3. Johanna K. DiStefano. Disease Gene Identification. Methods and Protocols. Springer New York Dordrecht Heidelberg London.
4. Hugo Kubiny. QSAR: Hansch Analysis and Related Approaches. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH
5. Klaus Gubernator, Hans-Joachim Böhm. Structure-Based Ligand Design. Methods and Principles in Medicinal Chemistry. Publisher Wiley-VCH
6. Abby L . Parrill. M . Rami Reddy. Rational Drug Design. Novel Methodology and Practical Applications. ACS Symposium Series; American Chemical Society: Washington, DC, 1999.
7. J. Rick Turner. New drug development design, methodology and, analysis. John Wiley & Sons, Inc., New Jersey.

CLINICAL RESEARCH AND PHARMACOVIGILANCE
(MPL 204T)

Scope:

This subject will provide a value addition and current requirement for the students in clinical research and pharmacovigilance. It will teach the students on conceptualizing, designing, conducting, managing and reporting of clinical trials. This subject also focuses on global scenario of Pharmacovigilance in different methods that can be used to generate safety data. It will teach the students in developing drug safety data in Pre-clinical, Clinical phases of Drug development and post market surveillance.

Objectives:

Upon completion of the course, the student shall be able to,

- Explain the regulatory requirements for conducting clinical trial
- Demonstrate the types of clinical trial designs
- Explain the responsibilities of key players involved in clinical trials
- Execute safety monitoring, reporting and close-out activities
- Explain the principles of Pharmacovigilance
- Detect new adverse drug reactions and their assessment
- Perform the adverse drug reaction reporting systems and communication in Pharmacovigilance

THEORY

60 Hrs

- | | | |
|----|---|-----------|
| 1. | Regulatory Perspectives of Clinical Trials:
Origin and Principles of International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines
Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant-Schedule Y, ICMR
Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process | 12
Hrs |
| 2 | Clinical Trials: Types and Design
Experimental Study- RCT and Non RCT,
Observation Study: Cohort, Case Control, Cross sectional
Clinical Trial Study Team
Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management | 12
Hrs |

- | | | |
|---|--|-----------|
| 3 | <p>Clinical Trial Documentation- Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring-Safety Monitoring in CT</p> <p>Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.</p> | 12
Hrs |
| 4 | <p>Basic aspects, terminologies and establishment of pharmacovigilance</p> <p>History and progress of pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing pharmacovigilance centres in Hospitals, Industry and National programmes related to pharmacovigilance. Roles and responsibilities in Pharmacovigilance</p> | 12
Hrs |
| 5 | <p>Methods, ADR reporting and tools used in Pharmacovigilance</p> <p>International classification of diseases, International Non-proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data.</p> | 12
Hrs |
| 6 | <p>Pharmacoepidemiology, pharmacoconomics, safety pharmacology</p> | 12
Hrs |

REFERENCES

1. Central Drugs Standard Control Organization- Good Clinical Practices, Guidelines for Clinical Trials on Pharmaceutical Products in India. New Delhi: Ministry of Health;2001.
2. International Conference on Harmonization of Technical requirements for registration of Pharmaceuticals for human use. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice.E6; May 1996.

3. Ethical Guidelines for Biomedical Research on Human Subjects 2000. Indian Council of Medical Research, New Delhi.
4. Textbook of Clinical Trials edited by David Machin, Simon Day and Sylvan Green, March 2005, John Wiley and Sons.
5. Clinical Data Management edited by R K Rondels, S A Varley, C F Webbs. Second Edition, Jan 2000, Wiley Publications.
6. Handbook of clinical Research. Julia Lloyd and Ann Raven Ed. Churchill Livingstone.
7. Principles of Clinical Research edited by Giovanna di Ignazio, Di Giovanna and Haynes.

PHARMACOLOGICAL PRACTICAL - II

(MPL 205P)

1. To record the DRC of agonist using suitable isolated tissues preparation.
2. To study the effects of antagonist/potentiating agents on DRC of agonist using suitable isolated tissue preparation.
3. To determine to the strength of unknown sample by matching bioassay by using suitable tissue preparation.
4. To determine to the strength of unknown sample by interpolation bioassay by using suitable tissue preparation
5. To determine to the strength of unknown sample by bracketing bioassay by using suitable tissue preparation
6. To determine to the strength of unknown sample by multiple point bioassay by using suitable tissue preparation.
7. Estimation of PA_2 values of various antagonists using suitable isolated tissue preparations.
8. To study the effects of various drugs on isolated heart preparations
9. Recording of rat BP, heart rate and ECG.
10. Recording of rat ECG
11. Drug absorption studies by averted rat ileum preparation.
12. Acute oral toxicity studies as per OECD guidelines.
13. Acute dermal toxicity studies as per OECD guidelines.
14. Repeated dose toxicity studies- Serum biochemical, haematological, urine analysis, functional observation tests and histological studies.
15. Drug mutagenicity study using mice bone-marrow chromosomal aberration test.
16. Protocol design for clinical trial.(3 Nos.)
17. Design of ADR monitoring protocol.
18. In-silico docking studies. (2 Nos.)
19. In-silico pharmacophore based screening.
20. In-silico QSAR studies.
21. ADR reporting

REFERENCES

1. Fundamentals of experimental Pharmacology-by M.N.Ghosh
2. Hand book of Experimental Pharmacology-S.K.Kulakarni
3. Text book of in-vitro practical Pharmacology by Ian Kitchen
4. Bioassay Techniques for Drug Development by Atta-ur-Rahman, Iqbal choudhary and William Thomsen
5. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.
6. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists.

